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Discovering how bacteria regulate their virulence mechanisms deepens our 
understanding of basic pathogenesis and allows us to uncover new potential targets for 
the treatment of disease. We applied a chemical genetics approach to probe the  cellular 
requirements for virulence gene expression in Vibrio cholerae by targeting the main 
virulence gene regulator, ToxT. The screen revealed two novel classes of inhibitors, 
toxtazins A and B. Both reduce cholera toxin production and production of an important 
ToxT-regulated pilus, the toxin co-regulated pilus. We present evidence that toxtazin A 
works by inhibiting toxT transcription, and may do this by activating stress pathways in 
the cell. We also demonstrate that toxtazin B works by  inhibiting tcpP transcription, and 
this may be due to a particular thiol switch in AphB,  one of two transcriptional activators 
required to activate the tcpP promoter. Furthermore, treatment with toxtazin B resulted 
in a 100-fold reduction in colonization in an infant mouse model of infection. These 
results add to the growing body of literature indicating that small molecule inhibitors of 
virulence genes could be developed to treat infections and to learn more about the basic 







Treatment of bacterial infections was revolutionized in the 1940s with the 
development of antibiotics (1).  Despite the huge initial success of antibiotic therapy, 
their overuse and misuse has led to their increasingly limited effectiveness.   Some 
antibiotics work by killing bacterial cells while others are bacteriostatic- both strategies 
that ensure resistant strains will have a strong selective advantage.  It is not surprising 
then, though certainly alarming, that for every antibiotic known there exists at least one 
resistant strain of bacteria (2).  Equally troubling is the fact that antibiotic therapy kills a 
large portion of the host microbiota as well as the offending pathogen.  The resulting 
dysbiosis can lead to acute and chronic intestinal problems (3, 4) and is one of the 
leading causes of hospital-acquired Clostridium difficile (5).   
The Center for Disease Control and Prevention recently estimated that 2,049,442 
illness are caused by antibiotic resistant bacteria and fungi annually, which result in over 
23,000 deaths, though this is likely an underestimation (6).  In addition to the health 
burden, antibiotic resistance also presents a significant financial burden, with estimates 
ranging from as high as $20 billion in direct healthcare costs and $35 billion in loss of 
productivity (6, 7).   
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As more and more pathogens become resistant to our antibiotics, and as we 
become increasingly aware of the protective effects of the microbiota, researchers have 
started to look for alternative therapies for treating bacterial infections.  Anti-infective 
drugs are attractive alternatives because they disarm pathogens rather than killing them, 
providing some advantages over antibiotic treatment.  First, any resistance developed 
against anti-infective drugs man have a weaker selective pressure, thus resistance 
would take longer to develop, if it developed at all.  Second, by targeting virulence traits, 
these anti-infectives will affect only the bacteria that possess those pathogenic traits- 
ideally leaving the microbiota relatively unaffected. 
Anti-infective compounds have another important role in biomedical research 
because of their potential to uncover new virulence requirements and further our basic 
biological understanding of pathogenesis.  There are several advantages to probing 
pathogenesis with small molecules at the bench: i) they act quickly, ii) they may be 
reversible or non-reversible, iii) they do not require manipulation of the genome, a 
quality that is especially advantageous in studying genetically intractable organisms, iv) 
the dose can be adjusted to fine-tune the effects, and v) they can be used across 
multiple bacterial species to determine how conserved a pathway is between different 
species or strains. 
Pathogenic bacteria have evolved countless strategies for establishing infection 
and causing disease in their various hosts.  For any given pathogen, there are 
numerous steps in the infectious process that can be inhibited to reduce the virulence 




Figure 1.1 Steps critical for bacterial pathogenesis.   
Presented here are fifteen events that are required for virulence in one or more 
pathogenic bacteria.  Some of these events deal with bacterial gene regulation, others 
are involved in host-pathogen interactions, and others affect bacterial structures such as 
pili and the chromosomal segregation machinery. 
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generalized model of pathogenesis, combining aspects of pathogenesis that are 
sometimes unique to one organism (for example, actin-mediated cell-to-cell spread is 
used by Listeria monocytogenes) or conserved in all bacteria (such as chromosomal 
segregation).  Figure 1.1 depicts the many facets of pathogenesis for which a small 
molecule inhibitor exists that is discussed here.  This serves to illustrate that these 
“Achilles’ heels” of pathogenesis, many of which were discovered using chemical 
genetics, can be exploited to develop new treatment therapies.  For simplicity, these 
small molecule inhibitors are grouped into three categories: those that regulate virulence 
genes, those that affect host-pathogen interactions, and those that alter the formation of 
important microbial structures.  We present examples of small molecules (summarized 
in Table 1.1) that have deepened our understanding of the fundamental processes in 
each of these areas.  We discuss how these discoveries have influenced our 
understanding of pathogenesis and how they have uncovered new potential drug 
targets.  We explore the advantages and limitations of small molecule research, and 
conclude with some ways in which small molecule screens could further our 
understanding of pathogenesis. 
 
Small molecules that regulate bacterial virulence gene expression 
Many published chemical genetic screens have targeted bacterial virulence 
factors, an approach that boasts numerous advantages.  First, because this treatment 
strategy uses anti-virulence compounds to disarm the pathogen rather than killing it, the 
host microbiota would presumably suffer less damage than it does with traditional. 
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Table 1.1 Small molecules discussed in this introduction. 
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antibiotics.  Secondly, these molecules theoretically impose less of a selective pressure 
than traditional antibiotics, reducing the risk for the emergence of resistant strains.  
Third, small molecule inhibitors can be designed with varying species specificity 
depending on how conserved the target is, allowing a compound to target a single 
species or a range of species.  Finally, anti-virulence molecules are also valuable as 
research tools, as they deepen our understanding of the molecular mechanisms 
required for virulence gene activation.  One early example of such a molecule is virstatin. 
 
Virstatin 
Virstatin (see Table 1.1) is a small molecule that inhibits toxin production in Vibrio 
cholerae (#1 in Figure 1.1) (8).  Virstatin was identified using a reporter strain of V. 
cholerae that has the cholera toxin promoter driving expression of the tetracycline 
resistance gene tetA.  In the presence of a compound that inhibits expression of the 
cholera toxin genes, this strain cannot grow in tetracycline-containing media.  The 
reporter strain was grown under standard toxin-inducing conditions with tetracycline and 
a library of compounds was added to each well.  One hundred and nine compounds 
were identified that inhibit growth in this assay, 15 of which had low bacterial toxicity in 
the absence of tetracycline.  One compound, ultimately termed virstatin, was chosen for 
follow-up studies. 
Target identification is one of the largest challenges posed to researchers after 
performing a cell-based reporter screen because the compound could target any step 
prior to expression of the reporter.  This is particular challenging because the target i) 
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may have an unspecified role in virulence; ii) may only be expressed under certain 
conditions, and/or iii) may not be a single protein but rather could be a protein complex 
or not a protein at all but rather DNA, RNA, lipids, or the redox state of the cell, to name 
a few. 
In the case of virstatin, advantage was taken of the fact that the virulence 
regulatory cascade in V. cholerae is well defined (28-34).  Expression profiles of genes 
expressed upstream of cholera toxin transcription in the regulatory cascade were 
examined and none were affected by virstatin.  When ToxT, the transcriptional activator 
of the ctx promoter, was ectopically over-expressed in the presence of virstatin, cells 
were still sensitive to virstatin, indicating that virstatin inhibits the activity of ToxT rather 
than its transcription or translation (8). 
Knowing that the target of virstatin was likely ToxT, the mechanism of action 
(MOA) of virstatin was investigated next.  A library of toxT mutant alleles was screened 
and a virstatin-resistant allele, toxTL113P, was identified (8).  The protein expressed from 
this mutant allele resembled wild type ToxT in that it was found predominantly in the 
multimeric form; however, in the presence of virstatin, wild-type ToxT is largely found as 
monomers, while ToxTL113P remains predominantly multimeric (9).  This led to the 
discovery that ToxT activation at the ctx promoter requires ToxT dimerization.  In fact, 
follow up work discovered that the oligomerization state of ToxT affects its activity at 
other ToxT-dependent promoters, with some promoters favoring the monomeric form 
and others favoring dimerized ToxT (35). 
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To assess its in vivo efficacy, virstatin was tested in an infant mouse model of V. 
cholerae colonization (8).  Mice inoculated with wild type V. cholerae and given virstatin 
had a 4-log decrease in colonization relative to mice given the DMSO control.  As a 
control, a strain of V. cholerae was used that colonizes the mouse in a ToxT-
independent manner and should therefore be unaffected by virstatin.  Whereas this 
strain colonized mice treated with the DMSO control or virstatin equally well, the more 
typical epidemic strain that requires ToxT for colonization colonized DMSO-treated mice 
much better than virstatin-treated mice, indicating that virstatin reduces colonization of V. 
cholerae by inhibiting ToxT activity in vivo. 
The fact that virstatin can be used as an in vivo molecular probe to differentiate 
strains of V. cholerae that require ToxT for colonization from those that do not has 
proven very useful.  In subsequent studies, virstatin was used to study the mechanisms 
by which non O1/non-O139 V. cholerae strains, which only cause sporadic disease, 
colonize their hosts (10).  Although it remains to be directly tested, that ToxT-
independent colonizing strains of V. cholerae are not affected by virstatin suggests that 
other bacteria lacking ToxT, including the host microbiota, would be unaffected by 
virstatin treatment, making virstatin an attractive therapeutic lead. 
The virstatin work advanced the field of V. cholerae research by revealing the 
importance of the dimerization state of ToxT, a level of regulation that was previously 
only suggested.  Furthermore, it provided a molecular probe that can be used in vivo to 
determine whether a V. cholerae isolate colonizes in a ToxT-dependent or independent 
manner.  Finally, as a compound that significantly reduces colonization of a pathogen by 
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specifically inhibiting its virulence factors in vivo, it provides a proof-of-principle for the 
concept of anti-virulence drugs.   
 
Fluoro-phenyl-styrene-sulfonamide (FPSS) 
Unlike virstatin, which targets a species-specific virulence regulator and its 
regulon, fluoro-phenyl-styrene-sulfonamide (FPSS) targets a general regulatory 
cascade- the sigma B (σB) regulon (#4 in Figure 1.1) (11).  Sigma factors are 
dissociable subunits of RNA polymerase (RNAP) that associate with RNAP in response 
to certain environmental signals and directly activate or repress a subset of genes, 
resulting in a rapid change in global transcription that is appropriate for the given 
environment.  Different sigma factors respond to different sets of environmental signals, 
allowing bacteria to quickly respond to specific environments.  In Listeria 
monocytogenes, σB responds to environmental stress (i.e.  acidic conditions, ethanol, 
or high salt concentrations), energy stress, and growth at high or low temperatures (36).  
In response to these signals, σB activates or represses genes involved in central 
metabolism and activates PrfA, the master regulator of virulence (37). 
Sigma factor inhibitors enable researchers to study the response of a specific 
sigma factor in isolation.  This is critical because cellular responses to different 
environmental conditions are often complex.  Different sigma factors can respond to the 
same signal, and different sigma factors can regulate the same genes in response to 
distinct signals, creating a complex web of regulation (38).  The contributions of 
individual sigma factors and of different environmental signals can be assessed with 
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specific sigma inhibitors.  This class of inhibitor may also have therapeutic potential 
because in some pathogens, sigma factors regulate virulence gene expression (39-41) 
(Reviewed in (42)). 
FPSS was identified using a cell-based reporter assay (11).  The screening strain 
contained a σB-dependent promoter, opuCA, fused to the gene for glucuronidase, gus, 
such that glucuronidase activity could be used as a readout for σB activity.  Using this 
assay, approximately 57,000 compounds were screened, and FPSS was identified as 
the best inhibitor of σB activity in live L. monocytogenes cells. 
FPSS inhibition of σB activity was confirmed by qRT-PCR, which showed that it 
inhibits opuCA transcription as well as another σB-dependent promoter, gadA, and does 
so in a dose-dependent manner.  In fact, transcription of σB-dependent promoters was 
decreased to the level of a σB mutant, indicating that FPSS can completely inhibit σB 
activity at these promoters.  Microarray analysis showed that FPSS-treated L. 
monocytogenes cells phenocopy a L. monocytogenes σB mutant, affecting 91% of 
genes identified as being σB-regulated in two or more previous studies (11).  As an 
example of the power of small molecule probes in research, FPSS also affected 83 
other genes, which excluding side effects, could potentially expanding the σB regulon.  
Gene set enrichment analysis (GSEA) determined that genes specifically regulated by 
σH or σL are not significantly enriched among genes differentially transcribed in FPSS-
treated cells, suggesting that FPSS affects σB specifically, and not sigma factors in 
general. 
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Bacillus subtilis was used to determine the MOA by which FPSS inhibits σB 
activity because its σB activity is also inhibited by FPSS (11) and because its well-
characterized σB regulon is highly conserved with the poorly understood σB regulon of 
L. monocytogenes.  In B. subtilis, σB activity is regulated by three distinct branches 
(shown in Figure 1.2 and reviewed in (43)): one branch relays environmental stress (i.e.  
acidic conditions, ethanol, or high salt concentrations), another branch relays energy 
stress (i.e.  limitation of glucose, ATP, GTP, of phosphate), and a third branch activates 
σB in response to growth at low temperatures. 
In B. subtilis, σB is kept in an off state by interaction with an anti-sigma factor, 
RsbW.  The ability of RsbW to sequester σB is controlled by a phosphorylated protein, 
RsbV.  In the phosphorylated state RsbV cannot bind RsbW, so RsbW is free to 
sequester σB and the σB regulon is not expressed.  When RsbV is unphosphorylated it 
binds RsbW, liberating σB, leading to activation of the σB regulon (44).  RsbV 
phosphorylation is controlled by both environmental stress and energy stress (45).  It 
was experimentally determined that FPSS inhibits σB activation by all three activation 
branches, indicating that it works on a factor common to all three branches (11).  The 
possibility that FPSS could bind or interact with σB was ruled out with both in vitro and 
in vivo experiments (12).  In addition, FPSS was shown to prevent RsbV 
phosphorylation (12).  Taken together, these results support a model whereby FPSS 
targets the partner-switching mechanism between RNA polymerase, σB, and its anti-
sigma factor, RsbW.  FPSS affords a unique tool to study σB activity in multiple 
organisms.  Microarray analysis of FPSS-treated cultures generated a list of 83  
13 
 
Figure 1.2 Bacillus subtilis regulates sigma B in response to stress. 
Energy stress, environmental stress, and growth at low temperature are all 
signals that can activate σB activity in B. subtilis.  Energy stress is relayed via RsbPQ, 
environmental stress is relayed via the stressosome and RsbU, and low temperatures 
are relayed via an unknown mechanism.  All three stresses impinge upon the 
phosphorylation of RsbV, the anti-anti-sigma factor.  When RsbV is phosphorylated, 
RsbW binds σB and the regulon is turned off.  Sensing stress results in 
dephosphorylation of RsbV allowing it to bind RsbW and releasing σB, which interacts 
with RNAP and activates the σB regulon. 
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potentially σB-regulated genes (11), which merit further study as they could broaden 
understanding of σB activity.  While animal studies with FPSS have not been reported, 
σB is an attractive therapeutic target because it is conserved in many pathogenic 
bacteria and is important in activation of virulence genes in several pathogenic bacteria 
(46-48).  One potential drawback to the therapeutic potential of this molecule, however, 
is that σB is found in many bacteria including commensal strains of the microbiota, and 
may cause dysbiosis of the microbiota.  This possibility remains to be determined. 
 
CCG-2979 
CCG-2979 (see Table 1.1 for structure) inhibits virulence by ultimately affecting 
the host response (See #3 in Figure 1.1).  It targets the promoter of streptokinase (SK) 
(13), a host-specific virulence factor secreted by Streptococcus pyogenes and other 
group A streptococci (GAS), which activates the host zymogen plasminogen to form 
plasmin, the central protease of the fibrinolytic system critical for regulating blood clots 
(49, 50).  The screen in which it was identified used a cell-based assay in which the SK 
gene promoter, ska, controlled expression of the kanamycin resistance gene; hits were 
considered those that decreased the growth of the reporter strain but not growth of a 
constitutive kanamycin-resistant strain.  After screening 55,000 compounds, hits were 
triaged based on activity, commercial availability, bioavailability prediction, and low 
activity in other screens performed at that screening facility, and CCG-2979 was 
identified (13). 
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CCG-2979 reduces SK activity in a dose-dependent manner without inhibiting 
bacterial growth.  Furthermore, GAS treated with five or 50 μM CCG-2979 were more 
susceptible to phagocytosis by host cells.  To determine the effects of this molecule on 
bacterial gene expression, the effects of CCG-102487, a CCG-2979 analog, were 
investigated by microarray.  The results showed that about 29% of GAS genes were 
altered by CCG-102487, including many virulence factors, genes involved in metabolism 
and energy production, as well as ska (13). 
Because SK is host-specific, transgenic mice expressing the human plasminogen 
gene were used to determine the therapeutic potential of CCG-2979.  Using this well-
established model (50), mice were subcutaneously injected with GAS, given a day to 
establish an infection, then treated with compound intraperitoneally daily for five days.  
While CCG-102487 did not protect mice from GAS-induced mortality, CCG-2979-treated 
mice showed a statistically significant improvement in survival (13). 
To determine the pharmacophore of CCG-2979, i.e.  the chemical features 
essential for biological activity, its structure was altered and structure-activity 
relationship (SAR) studies were performed (14, 15).  With this information, an analog 
(CCG-203592) was identified with a 35-fold increase in SK inhibition (14).  S. aureus is 
also a major public health problem because it can form biofilms on implantable devices 
(51).  CCG-203592 was found to inhibited biofilm formation of three different biofilm-
producing GAS strains both in laboratory microtiter plates and on silicone, the most 
common surface used for implantable medical devices (14).  These findings indicate 
that CCG-203592 may have therapeutic uses not only in clearing pre-formed GAS 
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infections, but also in preventing GAS biofilm formation on medical implants, making it 
an effective therapeutic lead. 
 
Small Molecules that affect Host-Pathogen Interactions 
Small molecules can provide valuable insight into underlying biological 
mechanisms in pathogenicity, and provide a relevant system for studying pathogens in 
the context of their hosts.  Instead of screening compounds of unknown function for 
inhibition of pathogenesis, one can also screen compounds whose cellular effects have 
been previously characterized.   
 
Pimozide 
Pimozide (see table 1.1 for structure) was identified from a library of compounds 
with previously known cellular targets as one that inhibits Listeria monocytogenes 
infection (16).  Pimozide is an FDA-approved antipsychotic molecule used to treat 
severe Tourette’s syndrome and schizophrenia (52).  Because the target is already 
known, such screens makes it easier to discover what processes are required for 
pathogenesis compared to a more open-ended screen with a large, diverse chemical 
library.  L. monocytogenes infects macrophages (53) after which it escapes the 
phagocytic vacuole by producing a hemolysin, listeriolysin O (LLO) (#14 in Figure 1.1), 
and replicates in the cytosol before spreading to neighboring cells by polymerizing host 
cell actin to propel itself into adjacent cells (54, 55).  While genetic and cellular biological 
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studies have uncovered much about L. monocytogenes pathogenicity, mechanisms 
regulating infection remain incompletely defined.   
A chemical genetics approach was taken in which both bacteria and host cells 
were exposed to compounds (16).  Primary bone marrow-derived macrophages (BMMs) 
were infected with L. monocytogenes constitutively expressing GFP to enable 
visualization of internalized bacteria.  Four hundred and eighty compounds with diverse, 
known biological activities were screened, and 21 were found to alter L. monocytogenes 
infection in one of three ways, each of which could be monitored using GFP (16).  The 
majority of inhibitory compounds inhibited BMM infection, as seen by a decrease in GFP 
fluorescence in BMMs relative to the DMSO control.  Others enhanced bacterial uptake 
or intracellular replication, causing an increase in GFP fluorescence per BMM cell.  
Lastly, some compounds inhibited cell-to-cell spread (#15 in Figure 1.1), seen as an 
increase in GFP fluorescence per BMM, but only in very few cells.   
Compounds that answered the screen fall into four categories based on the 
activities that they disrupt, and each category engenders testable hypotheses about 
conditions required for L. monocytogenes infection.  The first category includes 
compounds that disrupt actin, which is required for phagocytosis of bacteria by BMMs 
and for cell-to-cell spread of L. monocytogenes (55); two compounds from the screen 
fall into this category.  A second group of hits consists of four kinases/phosphatases.  
Such enzymes are important for actin rearrangement and were not further analyzed, 
though further study of these compounds could provide new insights on the role of 
specific kinases and phosphatases in L. monocytogenes infection.  Six more 
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compounds were categorized together on the basis of lacking shared activities with 
other compounds from the screen; further studies on these may also yield new insights 
into L. monocytogenes infection.  The fourth category, composed of nine compounds 
(43% of the hits), includes molecules that affect calcium pathways and probably play 
diverse roles in Listeria pathogenicity.  Not only is calcium important in many cellular 
signaling pathways including phagocytosis (56), it is also released in response to 
protein kinase C (PKC) activation, which occurs during L. monocytogenes infection and 
modulates bacterial uptake and escape from the vacuole (57).  Pimozide falls into this 
fourth category, and was chosen for further study. 
Pimozide was shown to inhibit intracellular infection of BMMs by L. 
monocytogenes by one order of magnitude after a 10-hr treatment (16).  While the exact 
mechanism for this is unclear, pimozide inhibited infection at three distinct steps.  The 
most potent effect of pimozide was inhibition of macrophage phagocytosis of L. 
monocytogenes, as well as three other bacteria: B. subtilis, Salmonella enterica serovar 
Typhimurium, and Escherichia coli K12.  Internalization by pimozide was inhibited by 
99%, compared with by DMSO-treated BBM, and inhibition was calcium independent 
(16).  Pimozide also reduced vacuolar escape of L. monocytogenes by 26%, although 
this was not due to inhibition of LLO.  Finally, pimozide treatment decreased cell-to-cell 
spread by approximately 50% (16).   
This screen generated many testable hypotheses regarding the cellular 
requirements of L. monocytogenes infection and revealed that pimozide can be used to 
probe the molecular mechanisms for BMM phagocytosis of bacteria in general, and of L. 
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monocytogenes specifically.  This compound is an example of one that affects a 
particular host-pathogen system in multiple yet synergistic ways.  Compounds like 
pimozide are particularly interesting as molecular probes because they illustrate the 
inter-relatedness and similarities of otherwise apparently different pathogenic 
mechanisms.  Additionally, molecules like pimozide have increased therapeutic appeal 
because of the lowered probability of overcoming multiple effects by mutation.   
 
Type 4 secretion inhibitors  
Compounds with known biological activities have also been used to probe the 
type 4 secretion system (T4SS; also called the Icm/Dot Type IVB system) in Legionella 
pneumophila, which infects and replicates in lung alveolar macrophages and causes 
Legionnaires’ disease (#9 in Figure 1.1) (58, 59).  L. pneumophila avoids phagosome-
lysosome fusion by using its T4SS to secrete effectors that interfere with vesicular 
trafficking, the host innate immune response, phosphoinositide metabolism, and 
ubiquitination (reviewed in (60)).  Given its importance for intracellular survival and 
replication (61) the T4SS is an attractive target for drug development.  The T4SS can be 
activated by contact with the host cell (62), but other signals that trigger secretion of 
effectors are not well understood.   
Compounds with known biological targets were screened to probe more deeply 
the mechanisms of type 4 secretion in Legionella (18).  An effector protein (LepA) was 
fused to the TEM-1-β-lactamase (BlaM), which can cleave a green substrate CCF4 to a 
blue product.  Host cells were incubated with compounds for 24 hours, infected with the 
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L. pneumophila lepA-blaM reporter strain, and host-bacterial cell contact was initiated 
by a low-speed centrifugation step.  One hour later, CCF4 was added and fluorescence 
was measured two hours later to quantify the amount of cleaved and uncleaved CFF4 
(18). 
Of 2,640 compounds screened, 86 tested positive in the screen, and 22 
compounds remained after a triage step was performed to eliminate molecules that 
were toxic or inhibited the reporter itself (e.g.  fluorescence quenchers).  These 22 
molecules inhibit translocation with efficiencies ranging from 63 to 100% and were 
categorized into groups based on known activity, including ionophore/protonophores, 
inhibitors of calmodulin, cytoskeleton dynamics, NF-κB, serine proteases, kinases or 
phosphatases, and others (18). 
Ionophore/protonophores discharge membrane electric potential (Δψ) and 
collapse the proton gradient (pH), components of the PMF (#8 in Figure 1.1) (63, 64).  
All three identified ionophore/protonophores inhibited Icm/Dot-dependent lysis of red 
blood cells by L. pneumophila (18), indicating that translocation of effectors is at least 
partially dependent on the PMF.  Furthermore, one ionophore, CCCP (shown in Table 
1.1), inhibited LepA translocation in L. pneumophila in a dose-dependent and reversible 
manner (18).  The PMF was not previously known to play a role in T4SS-mediated 
translocation, so this discovery points to the value of small molecule screening for 
uncovering previously unknown pathogenicity mechanisms.   
The majority of the inhibitors identified in this screen are molecules previously 
known to affect host cytoskeleton dynamics, including molecules that affect tubulin (#12 
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in Figure 1.1), actin (#13 in Figure 1.1), and PI3K.  They likely inhibit phagocytosis (#10 
in Figure 1.1), a key function of macrophages.  In fact, 19 of the 22 identified inhibitors 
were found to significantly affect the ability of macrophages to phagocytose other 
bacteria (18).  To test whether phagocytosis is required for translocation of L. 
pneumophila Icm/Dot effector proteins, cytoskeleton inhibitors were used to inhibit 
coiling phagocytosis, the type of phagocytosis used by L. pneumophila to enter 
macrophages (65).  Host-bacterial contact was instead initiated by opsonization, a 
mechanism quite different from coiling phagocytosis (66).  Opsonization of L. 
pneumophila with L. pneumophila-specific antibodies restored effector translocation in 
the absence of phagocytosis.  That is, when host cells and L. pneumophila were co-
incubated with antibody, the cytoskeleton inhibitors did not increase the amount of 
bacterial uptake, but LepA and RalF were translocated to 90% of the level reached in 
DMSO- treated samples.  In fact, Fc signaling is not required for triggering translocation, 
because when CHO cells expressing a non-signaling mutant of the FC receptor FcγRIIA 
(Y2F/Y3F) were used, opsonization still stimulated translocation (18).  These results 
indicate that host-cell binding, and not phagocytosis, is required for translocation by the 
Icm/Dot system and supports a model where the T4SS in L. pneumophila is in a “locked 
and loaded” state, ready to inject effector proteins upon contact with a host cell (#11 in 
Figure 1.1). 
Another important finding made from this study came by further analyzing the 
translocation inhibitor, RWJ-60475 (shown in Table 1.1), which was previously known to 
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inhibit a receptor tyrosine phosphate phosphatase (67).  Work with this compound 
revealed that CD45 and CD148 are required to phagocytose L. pneumophila (18).   
From screening just 2,500 small molecules, a wealth of new information about 
the T4SS in L. pneumophila was uncovered and many new testable hypotheses were 
generated.  New information relating phagocytosis and effector translocation with PMF, 
host cell contact and CD45 or CD148 was uncovered, providing a good example of how 
chemical genetics can reveal pathogenicity mechanisms. 
 
LED209 
Pathogens generally initiate virulence gene expression in response to host 
environments.  As examples, E. coli, S. typhimurium, and Francisella tularensis, 
express a sensor histidine kinase called QseC that detects host-derived adrenergic 
signals (epinephrine and norepinephrine) as well as the quorum-sensing autoinducer-3 
(AI-3) (68, 69).  In response to either of these signals, QseC autophosphorylates then 
phosphorylates the transcription factor QseB, leading to transcription of key virulence 
genes including the LEE1 operon in enterohaemorrhagic E. coli (EHEC) (#6 in Figure 
1.1) (70).   
A chemical library of 150,000 compounds was screened for those that block 
expression of a LEE1-lacZ reporter strain (19).  Compounds were screened in an assay 
using spent media (which contains AI-3) to activate QseC and induce reporter gene 
expression.  The most potent inhibitor identified was ultimately improved by SAR and 
named LED209 (see Table 1.1 for structure) (19). 
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As expected, LED209 did not inhibit bacterial growth, but rather selectively 
inhibited virulence gene expression by inhibiting QseC autophosphorylation (19).  While 
LED209 was ineffective in an infant rabbit model of EHEC infection (perhaps due to 
rapid absorption from the gastrointestinal tract) (19), it significantly reduced mouse 
pathogenicity of both S. typhimurium and F. tularensis, which express QseC 
homologues of 87% and 57% similarity, respectively, to EHEC QseC (19).  QseC is 
important for motility in S. typhimurium (71) and for systemic infection in F. tularensis 
(72).   
Similar to virstatin, LED209 inhibits virulence by targeting a specific virulence 
regulator without affecting growth.  It is a particularly attractive drug candidate because 
its target, QseC, is conserved in over 25 pathogenic bacteria but absent in mammals 
(19), giving this molecule a bacteria-specific broad spectrum of activity.   
 
Small molecules that target structures 
Another effective anti-virulence strategy is inhibiting the formation of structures 
required for virulence.  Pathogens have multiple conserved mechanisms to deliver 
effector proteins into cells, such as the T4SS discussed above, and inhibiting the 
formation of structures critical for these mechanisms is an attractive anti-pathogen 




In addition to type 4 secretion, the type 3 secretion system (T3SS) injectosome 
has been targeted to develop therapeutic leads given its broad conservation in Gram-
negative pathogens (#7 in Figure 1.1).  A screen to inhibit the S. typhimurium T3SS was 
developed by using a reporter strain that secretes phospholipase in a T3SS-dependent 
manner (20).  Phospholipase activity of a culture was determined by adding the 
phospholipase substrate PED6, whose cleavage product is fluorescent and can be 
quantified on a plate reader.  After screening 92,000 natural and synthetic small 
molecules, 89 compounds were identified and triaged to exclude those with no novelty 
or potential for drug development, those that inhibit bacterial translation, inhibit sec-
dependent secretion and/or disulfide bond isomerization, or decrease expression of the 
T3SS components.  One compound, a 2-imino-5-arylidene thiazolidinone, was 
investigated further (20).  This compound, termed TTS29, inhibited effector secretion in 
a dose-dependent manner.  Needle complexes from cultures grown with TTS29 
displayed an overall reduction in protein levels, but the needle complex protein 
constituents were not reduced overall in whole cell lysates.  This finding indicated that 
the proteins were being produced, but that their assembly into the needle complex was 
inhibited by TTS29 (20).   
Because components of the T3SS are conserved in different bacteria, TTS29 has 
the potential to work against other T3S-encoding bacteria.  In Yersinia species, there 
are two types of T3SS: the plasmid-encoded Ysc system in Yersinia pestis, Yersinia 
enterocolitica, and Yersinia pseudotuberculosis, which secretes Yops (Yersinia outer 
25 
proteins) into the cytosol of target cells, and the chromosomally encoded Ysa system in 
Y. enterocolitica, which secrets Ysps (Yersinia secreted proteins) (77, 78).  TSS29 
inhibited secretion of both Yops and Ysps into Y. enterocolitica culture supernatants, 
indicating its potential utility as a broad inhibitor of T3SS (20).  In contrast, TSS29 did 
not alter flagellar motility or decrease the levels of flagellar components in either S. 
typhimurium or Pseudomonas aeruginosa, bacteria that depend on a flagellar-specific 
T3SS for flagellar motility (20).  This suggests that TSS29 targets a part of the T3SS 
that is not conserved with the evolutionarily related flagellar-specific T3SS (78).   
However, as one component of the T3SS is conserved in the type 2 secretion 
system (T2SS) that delivers enzymes and other proteins across the Gram-negative 
envelope (79), TSS29 was tested for its ability to inhibit such systems to determine if its 
target is shared between the two secretion systems.  Secretion of elastase (80) by the 
T2SS in P. aeruginosa was inhibited by TSS29, as was twitching motility, which is 
determined by the type four pilus (T4P) that has components similar to those of the 
T2SS (20).  These results demonstrate that TSS29 is a broad inhibitor of secretion that 
affects multiple secretion systems in multiple bacterial species.   
The in vivo effectiveness of TSS29 was supported by demonstrating its ability to 
reduce killing of bone marrow derived macrophages in a tissue culture model of 
infection (20).  It also inhibits Pseudomonas syringae pv tomato DC3000 from inducing 
a hypersensitivity response in Tobacco plants (20).  Thus, TSS29 has wide therapeutic 
potential because it can target a range of secretion systems in different bacterial 




A22 (shown in Table 1.1) has had a large impact on basic biology, having led the 
way to discoveries that unraveled the mystery behind bacterial replication, chromosome 
segregation, and cellular division (21, 22).  Prior to discovery of A22, it was known that 
maintaining a proper rod shape was required for chromosomal partitioning in E. coli (81), 
although how the rod shape was maintained or why it was required was less understood.  
A22 played a major role in uncovering the function of MreB in bacterial chromosome 
replication and division (#5 in Figure 1.1), and was instrumental in eliminating a 
previously proposed model of chromosomal segregation that hypothesized that 
replication may provide the driving force for segregation.   
This compound emerged in a screen for inhibitors of chromosome partitioning in 
E. coli; such molecules can induce formation of anucleate cells (21).  Anucleate cells 
arise when cells divide before correctly segregating replicated chromosomes (81).  
Unlike mecillinam, an antibiotic that specifically inhibits penicillin-binding protein 2 
(Pbp2) and thus blocks cell division, A22 bound none of the seven known PBPs in vitro, 
nor did it affect Pbp2 activity (21). 
The compound was helpful for probing the molecular mechanism underlying 
chromosome segregation.  Prior evidence suggested that MreB plays a role in 
chromosome segregation (82), but proving this was difficult because loss of mreB 
function is lethal and MreB depletion is slow and pleiotropic, disrupting processes 
unrelated to chromosome segregation such as cell shape, polar protein localization, and 
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cell division.  Further analysis of A22 determined that it directly targets MreB (22).  
Colonies resistant to the compound had missense mutations in the mreB gene, some of 
which mapped to a predicted ATP binding pocket or to a helix that could contact ATP in 
that pocket (22).  Biochemical experiments demonstrated MreB binds A22 with 
micromolar affinity in its nucleotide-binding pocket, which sterically inhibits ATP binding 
and prevents MreB polymerization (83). 
Unlike in untreated cells where MreB localized in spirals along the length of the 
cell and in rings around the site of cellular division (84-86), in A22-treated cells MreB 
was dispersed evenly (22).  Furthermore, when A22 was washed out of the cells, those 
that had MreB rings before A22 treatment recovered rings after A22 was washed out, 
cells that had spirals recovered spirals, and cells with partially compacted rings 
recovered partially compacted rings (22).  This finding indicated that MreB localization is 
determined by other factors and not by MreB itself.  Furthermore, the A22-resistant 
mutant (T158A) was unable to condense MreB into rings, suggesting that ATP 
hydrolysis is important for regulating MreB dynamics (22). 
Chromosome segregation was monitored using a fluorescent repressor-operator 
system (FROS) in the presence and absence of A22, revealing that the compound 
prevented segregation, although the cells doubled in size (22).  That A22 was simply 
inhibiting replication was ruled out by comparing incorporation of radiolabeled 
nucleotides in the presence of A22 or a known replication inhibitor hydroxyurea (HU) 
(22).  Thus, by investigating the mechanism of A22 action a previously unknown role for 
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MreB activity in chromosome segregation was identified, and a previous hypothesis 
proposing that replication drives segregation was ruled out.   
A22 has been a very useful tool for studying the mechanisms involved in cell 
shape maintenance and MreB function.  It led to the discovery that MreB exhibits 
treadmilling in vivo, similar to actin treadmilling in eukaryotes (#13 in Figure 1.1) (87), 
and was instrumental in demonstrating the localization pattern of the MreC protein (88).  
A22 was used to show that MreB activity is important for effector protein secretion in S. 
flexneri (23), for motility in Myxococcus xanthus (89), and for tethering lipid II 
biosynthesis in C. pneumoniae (90).  The fact that chromosome segregation is affected 
by A22 in many but not all MreB-encoding bacteria suggests that in some bacteria, 
alternate mechanisms exist for chromosome segregation (23).   
 
Pilicides 
While some microbes secrete pilus adherence structures through type 2-like 
secretion systems that can be inhibited by TSS29 as described above, others use pili 
assembled by pathways that rely on a periplasmic chaperone (91-93) and an outer 
membrane usher (94, 95) (see (96, 97) for reviews).  The chaperone mediates the 
folding, stabilization, and transport of pili subunits, while the usher incorporates the 
subunits into the growing pilus (97). 
Because this form of pilus assembly is so conserved in a wide range of 
pathogens (97), inhibitors that target the chaperone-usher systems are effective against 
a broad range of bacterial species.  Substituted bicyclic 2-pyridones, called pilicides 
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(pharmacophore shown in Table 1.1), are a well-studied group of synthetic small 
molecule inhibitors that prevent the formation of pili in Uropathogenic E. coli (UPEC) 
(97). 
 UPEC produce two types of disease-associated pili- P pili (encoded by the pap 
genes) and Type 1 pili (encoded by the fim genes) shown in Figure 1.3 (97).  P pili are 
made up of PapA (the major subunit), E, F, G, H, and K, and are assembled by the 
PapD chaperone and the PapC usher.  Type 1 pili are made up of FimA (the major 
subunit), G, and H, and are assembled by the chaperon FimC and the usher FimD (97).   
Whereas most small molecule inhibitors were discovered by screening 
compound libraries, pilicides were designed using a rational design approach (24).  
Knowing that pilus biogenesis requires the chaperone protein to bind its natural ligands 
(98), the solved crystal structure of the PapD-PapG complex was used to chemically 
design molecular mimetics that would bind within the active site of the periplasmic 
chaperones PapD and FimC (24).  A library of pilicides was synthesized and 
subsequently shown to be effective at inhibiting pilus formation by electron microscopy 
(27). 
After determining that pilicides do not affect cell growth or viability, pilicides were 
shown to inhibit pili-dependent phenotypes including type 1 pili-mediated mannose-
sensitive hemagglutination (MSHA) and P pili-mediated hemagglutination (HA), 
indicating that pilicides affect pili-dependent phenomena in vivo (27).  Pilicides also 
reduced biofilm formation and bacterial attachment to host cells, both of which are 




Figure 1.3 P pili and type 1 pili are structurally similar but encoded by different genes. 
A diagram illustrating the similarities and differences in the P pilus (encoded by 
papA-G) and the Type 1 pili (encoded by FimA-H).  Pili consist of several repeating 
subunits arranged in a helical structure.  These subunits are translocated from the 
cytoplasm to the periplasm where a chaperone (PapD or FimC) folds the protein, 
stabilizes it, and transfers it to the usher protein (PapC or FimD), which secretes the 
protein and incorporates it into the pilus structure.
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strains to adhere to cultured bladder cells by 90% (27).  Taken together, these results 
strongly indicate that pilicides inhibit production of both P pili and type 1 fimbriae in E. 
coli. 
To gain a deeper appreciation for the mechanism of pilicide inhibition, pilicide 2c 
was co-crystalized with the PapD chaperone (27).  The resulting crystal structure 
showed that pilicide 2c forms close contacts with a hydrophobic patch that runs across 
the back of the F1-C1-D1 beta sheet on PapD, a region that is highly conserved in all 
pili periplasmic chaperones, and which may mediate interactions between the 
periplasmic chaperone and the N-terminal domain of the usher protein (99).  The finding 
that pilicides bind to the site of chaperone-usher interaction suggests that pilicides work 
by preventing the interaction of the usher with the chaperone.  Supporting this proposed 
mechanism is the finding that a point mutation (R58A) in the hydrophobic patch of PapD 
displays a marked reduction in pili production but is still able to bind, fold, and stabilize 
pilus subunits (27).  Furthermore, pilicide 2c was shown to inhibit FimC-FimH from 
binding to FimD using surface plasmon resonance (27), indicating that pilicide 2c 
inhibits pili biogenesis by preventing the chaperone from passing the subunit to the 
usher. 
Pilicides have uncovered new knowledge about the molecular mechanisms 
involved in pili biogenesis, and serve as an example of how crystallography can guide 
chemists to create a small molecule with a predictable activity, a technique called 
structure-based drug design (SBDD).  SBDD is also useful for drug development 
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because resulting co-crystal structures provide information on compound-target binding 
interactions that can be modified to improve in the activity of the compound. 
 
Advantages and Challenges of Chemical Genetics 
Advantages 
Chemical genetics allows scientists to probe biological pathways in new ways, 
giving us a new perspective on the requirements of pathogenesis.  As biological probes, 
small molecule inhibitors are useful tools because they allow for the manipulation of 
processes that are genetically difficult to regulate.  For example, genes that are 
essential for viability (such as mreB) are difficult to study with conventional genetics, but 
can be easily studied using these compounds.  Genes whose deletion results in 
pleiotropic effects (such as sigma factors) can be more carefully studied with chemical 
inhibitors.  In organisms where genetic manipulation is impossible or very difficult and 
time consuming, small molecule inhibitors provide an alternative avenue for studying 
conditions required for pathogenesis.  In addition, small molecules act quickly, reversibly, 
and their effects can be titrated with dose.   
From a therapeutic perspective, small molecule studies serve as a starting point 
for drug development, and give insight into the druggability of a particular protein or 
molecular target.  Additionally, small molecules can be designed to target a certain 
species or a broad range of species by choosing a target that is specific to one 
organism or conserved among many species.  For example, virstatin was designed with 
extreme specificity, acting only on V. cholerae.  On the other hand, TSS29 inhibits the 
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type 3 secretion system, which is conserved across many species of bacteria, and 
therefore has a broader range of activity.   
 
Challenges 
Despite the wealth of information gained from chemical genetics, there are 
challenges inherent to small molecule screens.  For one, compounds can have multiple 
targets and/or side effects (e.g. pimozide), which can confound the interpretation of 
results.  Because of this, experiments with small molecules must be carefully controlled.   
Possibly the largest hurdle in studying compounds identified in chemical screens 
is the precise identification of their molecular targets and elucidation of their 
mechanisms of action.  New methods for target identification are constantly being 
developed and improved and have recently been the subject of a review (100).  
Screening molecules of known biological function helps avoid this issue altogether; 
however, some molecules have more than one biological activity, which can confound 
target identification and characterization.   
One method of discovering the target of an inhibitor is to use a targeted “loss-of-
target” approach.  An example of this was demonstrated in uncovering the target of 
virstatin by testing known components of the toxin regulatory cascade to determine what 
was or was not affected by virstatin (8).  After identifying ToxT as the target, the 
mechanism of virstatin action was investigated by screening for resistant mutants (8).  
As sequencing of entire genomes becomes more affordable, this method is becoming 
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increasingly useful.  This loss-of-target approach was also used to identify targets of 
LED209 (19) and of TTS29 (20).   
Another approach for target identification is to compare gene expression profiles 
of cells in the presence or absence of the inhibitor, which, combined with gene set 
enrichment analysis (GSEA), was used to determine the target of FPSS (11).  Along the 
same vein, insight on the mechanism of a compounds activity can be gained by using 
technologies such as MUDpit (101) to analyze global changes in protein levels, or 
RNAseq (102) to look at global changes in transcript levels of both coding and non-
coding RNAs. 
In recent years, click-chemistry has also been adapted to uncover binding 
partner(s) of small molecules (103).  In this approach, a small molecule inhibitor is 
modified such that it has two reactive handles.  The first will “click” the small molecule to 
its target, covalently linking the compound to its target.  The second handle can be 
biotinylated, allowing the compound-target complex to be purified on a column.  After a 
series of washes, the eluate is analyzed by mass spectrometry to identify the protein(s) 
with which the small molecule interacts.   
Understanding the mechanisms by which bacteria regulate virulence and cause 
disease has long been an area of active research.  The use of chemical genetics has 
enriched this field by enabling us to deepen our knowledge of the basic molecular 
mechanisms underlying pathogenesis while simultaneously testing the druggability of 
these mechanisms.  In many cases, chemical genetic studies have provided lead 
compounds with therapeutic potential that can be developed into treatment therapies.   
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Vibrio cholerae pathogenesis 
For this thesis, a chemical genetics approach was used to probe the cellular 
requirements for virulence gene expression in Vibrio cholerae.  V. cholerae is a Gram-
negative rod that causes the human disease cholera (104).  Found in coastal regions 
world-wide, it can live planktonically in fresh or brackish waters, or in association with 
copepods (105).  V. cholerae is transmitted to humans either by the fecal-oral route, or 
by consumption of contaminated food or water allowing the bacteria access to the upper 
small intestine, where they secrete cholera toxin (CT; encoded by the genes ctxAB) 
(106).  CT binds to and enters intestinal epithelial cells and increases cAMP production 
(106) causing a decrease in sodium uptake and an accompanying increase in chloride 
secretion, resulting in secretion of water into the lumen of the intestine and leading to 
severe diarrhea and dehydration (107). 
The main method of treating cholera is oral rehydration therapy (ORT), in which a 
solution of glucose, sodium, potassium, and citrate is administered to counteract the 
severe dehydration caused by CT (108, 109).  While antibiotics are effective at killing 
most V. cholerae strains, they do little to offset the severe diarrhea and dehydration 
caused by V. cholerae, and are therefore not sufficient as a monotherapy and are 
instead used to supplement ORT (104, 108).   
The model in Figure 2.6 of Chapter 2 depicts the cascade of transcriptional 
regulators that control virulence in V. cholerae (110).  ToxT, shown in orange, is the 
master regulator of virulence and activates over 20 genes, including CT and a 
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colonization factor, the toxin co-regulated pilus (TCP) (34).  Transcription of toxT is 
regulated by a unique complex of inner membrane proteins, ToxR and its effector 
protein ToxS, and TcpP and its effector protein TcpH (31, 33, 110-113).  The tcpPH 
operon is highly transcriptionally regulated, with AphA and AphB required to activate 
transcription of the tcpP promoter (114, 115), while HNS (116), cAMP-CRP (117), and 
PhoB (118) are known to repress tcpP transcription.   
TcpP is also regulated at the post-translational level.  When cells are shifted from 
growth under toxin-inducing to non-inducing conditions, TcpP is degraded by a two-step 
process.  The site 1 protease, Tsp, cleaves TcpP in the inner membrane (Teoh, W.P.  
and DiRita, V.J., unpublished), producing the substrate for YaeL cleavage (119), and 
complete degradation of TcpP, resulting in the termination of the virulence cascade. 
As noted above, a small molecule inhibitor of ToxT function, virstatin, was 
identified by screening a compound library for inhibitors of ctx gene expression (8).  For 
my thesis research, a small molecule screen was performed to identify compounds that 
inhibit expression of toxT, and these would be predicted to decrease CT production in V. 
cholerae.  Such a compound could theoretically reduce disease severity and duration, 
and would therefore be potentially useful in treating cholera in regions of the world 
where cholera is endemic, and would also have potential as a prophylactic in areas 
such as refugee camps or military bases that suffer frequent cholera outbreaks. 
While the compounds identified in this small molecule screen would need 
decades of development before being potentially used for human health, their value as 
molecular probes can be exploited right away to deepen our understanding of the 
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cellular requirements for V. cholerae pathogenesis, and this is the focus of my 
dissertation.   
 
This dissertation describes the identification and characterization of toxtazins A 
and B, small molecules that inhibit toxT gene expression leading to decreases in 
expression of genes encoding toxin and toxin-coregulated pilus.  The two toxtazin 
molecules act at distinct steps in the regulatory pathway and one of them, toxtazin B, 
























































































































































































































































































































































































Small molecule inhibitors of toxT expression in Vibrio cholerae 
Note: A modified version of this text has been published (Anthouard R, DiRita VJ. 2013. 
Small-molecule inhibitors of toxT expression in Vibrio cholerae. mBio 4). 
 
Summary 
Vibrio cholerae, a Gram-negative bacterium, infects humans and causes cholera, 
a severe disease characterized by vomiting and diarrhea.  These symptoms are 
primarily caused by cholera toxin (CT), whose production by V. cholerae is tightly 
regulated by the virulence cascade.  In this study, we designed and carried out a high-
throughput chemical genetic screen to identify inhibitors of the virulence cascade.  We 
identified three compounds, toxtazin A and toxtazin B and B’, representing two novel 
classes of toxT transcription inhibitors.  All three compounds reduce production of both 
CT and the toxin co-regulated pilus (TCP), an important colonization factor.  We present 
evidence that toxtazin A works at the level of the toxT promoter, and that toxtazins B 
and B’ work at the level of the tcpP promoter.  Treatment with toxtazin B results in a 
100-fold reduction in colonization in an infant mouse model of infection, though toxtazin 
A did not reduce colonization at the concentrations tested.  These results add to the 
growing body of literature indicating that small molecule inhibitors of virulence genes 
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could be developed to treat infections, as alternatives to antibiotics become increasingly 
needed. 
V. cholerae caused more than 580,000 infections worldwide in 2011 alone (1).  
Cholera is treated with an oral rehydration therapy consisting of water, glucose, and 
electrolytes.  However, as V. cholerae is transmitted via contaminated water, treatment 
can be difficult for communities whose water source is contaminated.  In this study, we 
address the need for new therapeutic approaches by targeting the production of the 
main virulence factor, CT.  The high-throughput screen presented here led to the 
identification of two novel classes of inhibitors of the virulence cascade in V. cholerae, 
toxtazins A and toxtazins B and B’.  We demonstrate that i) small molecules inhibitors of 
virulence gene production can be identified in a high-throughput screen ii), targeting 
virulence gene production is an effective therapeutic strategy, and iii) small molecule 





Vibrio cholerae, a Gram-negative pathogen, colonizes the human intestine and 
causes cholera, an acute disease characterized by vomiting, profuse watery diarrhea 
and severe dehydration.  The symptoms are caused by the secreted cholera toxin (CT) 
(2), which binds and enters intestinal epithelial cells and increases cAMP production.  
This leads to a decrease in sodium uptake and a concomitant increase in chloride 
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extrusion into the lumen of the intestine, resulting in water secretion thus causing 
diarrhea and dehydration (3).   
Because CT is the major virulence factor produced by V. cholerae, much 
research has gone into understanding how its expression is regulated.  Epidemic strains 
of V. cholerae are divided into two biotypes, classical and El Tor, both of which regulate 
the virulence cascade via the master virulence regulator, ToxT (refer to Figure 2.6).  
Transcription of the ctxAB operon, which encodes the two CT subunits, and the tcp 
operon, which encodes the genes for the toxin co-regulated pilus (TCP), is activated by 
ToxT (4, 5).  Transcription of toxT is activated by a protein complex comprised of four 
inner membrane proteins ToxRS and TcpPH (6).  The transcription of tcpPH is activated 
by two transcription activators, AphA and AphB, which respond to cell density, 
anaerobiosis, and other factors (7-9).  
Currently, cholera is treated with oral rehydration therapy (ORT), which restores 
fluids to the patient and allows the immune system to clear the infection (10, 11).  
Antibiotics are sometimes administered as a second line of treatment, as they can 
reduce vomiting and diarrheal volume by 50% and shorten illness duration by 50%.  
However, antibiotics are not effective alone because patients are still at risk of severe 
dehydration caused by CT (10, 12).  Because of this, investigating other treatment 
modalities could provide benefit for the treatment of cholera, and this is an area of active 
research (13-15).  Previous work identified an inhibitor called virstatin, which inhibits 
ToxT dimerization and thereby alters its activity.  Further experiments using virstatin 
revealed that ToxT dimerization affects its activity at various promoters (16).  
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Interestingly, when ToxT was crystalized, it was bound to a sixteen-carbon fatty acid cis-
palmitoleate.  This and other similar fatty acid ligands were shown to hold ToxT in a 
closed conformation, inhibiting its ability to bind and activate the tcp and ctx promoters 
(17).  
Anti-virulence drugs are becoming an increasingly popular strategy in combating 
diseases.  Unlike antibiotics, anti-virulence drugs aim to disarm a pathogen by 
eliminating its virulence potential and allowing the immune system to clear the infection, 
providing several advantages.  First, targeting virulence genes imposes a weaker 
selective pressure than targeting growth, decreasing the potential for the emergence of 
resistant strains (18, 19).  In fact, in some conditions, spontaneous non-toxigenic 
mutants of V. cholerae outcompete the pathogenic wild type parental strains (20).  
Additionally, targeting pathogens with anti-virulence drugs has minimal effects on 
endogenous microbiota, diminishing the risk of dysbiosis caused by antibiotics that can 
lead to acute and chronic intestinal problems (21, 22). 
In addition to the potential therapeutic advantages of anti-virulence compounds, 
small molecules provide significant value as molecular probes for investigating the basic 
biology governing virulence.  Because such compounds do not kill bacteria, they can be 
used experimentally to probe virulence traits without genetic manipulation of the 
organism.  Compounds used as molecular probes act quickly, are often reversible, and 
their effects can be enhanced or diminished simply by changing the concentration. 
 In this study, we performed a high-throughput screen to identify small molecules 
that inhibit the expression of toxT.  We identified three compounds- toxtazin A, and 
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toxtazin B and B’; the latter two are structural analogs of each other.  All three 
compounds decrease CT and TCP levels.  We determined that toxtazin A does not 
affect the protein or transcript levels of the ToxR, TcpP, AphA, or AphB, the genes 
upstream of toxT in the virulence cascade, indicating that it prevents toxT transcription.  
Toxtazins B and B’ both inhibit virulence by decreasing TcpP protein and transcript 
levels but not AphA or AphB protein or transcript levels, indicating that these 




A GFP-based high-throughput screen identifies two novel classes of toxT expression 
inhibitors 
To identify small molecule inhibitors of toxT transcription that do not affect 
general growth, a reporter strain was constructed consisting of wild type V. cholerae 
harboring a plasmid on which the toxT promoter drives the expression of GFP.  
Culturing the toxT::gfp reporter strain NB39 under toxin-inducing conditions resulted in 
high fluorescence intensity units in a wild type background and relatively low 
fluorescence intensity units in the isogenic ΔtoxR strain NB40 (Figure 2.1A).  Molecules 
that decrease GFP expression in a wild type cell could be inhibiting any event in the 
virulence cascade prior to toxT transcription.  Using NB39, approximately 63,000 







Figure 2.1 Identification of inhibitors of the virulence cascade in V. cholerae.  
A. The wild type reporter strain NB39 has a high GFP/OD600 ratio when grown 
overnight under toxin-inducing conditions, while the isogenic ΔtoxR strain NB39 does 




Genomics.  A compound was scored as active if it reduced GFP fluorescence to a level 
lower than six standard deviations from the mean of the untreated controls, without 
decreasing growth (measured as changes in OD600) by greater than 10% of the 
untreated controls, indicating that the compound is not toxic at that dose.  Of the 1,411 
compounds that met these requirements, 175 exhibited dose-dependent inhibition of 
GFP fluorescence (Figure 2.1B).  We prioritized these based on potency, and 
purchased the top 50 compounds for further characterization.  We measured the levels 
of CT produced in cultures treated with the top 50 compounds by ELISA and selected 
the three compounds that resulted in the lowest level of toxin production for further 
characterization.  We named these toxtazins A, B, and B’, and their chemical structures 
are shown in Figure 2.1C.   
 
Toxtazin A, B, and B’ inhibit the virulence cascade 
To determine an optimal concentration for our experiments, cultures of NB39 
were inoculated overnight in toxin-inducing conditions, with various concentrations of 
compounds or the equivalent volume of DMSO.  Addition of compounds had significant 
and dose-dependent effects on GFP fluorescence (Figure 2.2A) and the half maximal 
effective concentrations (EC50) of toxtazins A, B, and B’ were 24.5 μM, 2.7 μM, and 7.2 
μM, respectively.  All three compounds had a statistically significant effect on growth at 
concentrations of 25 μM and higher (Figure 2.2B) and a statistically significant effect on 
GFP fluorescence at concentrations of 5 μM and higher.  Thus, subsequent in vitro 





Figure 2.2 Toxtazin A, B, and B’ inhibit the virulence cascade in V. cholerae. 
A and B.  GFP expression (2A) and terminal OD600 (2B) after 16 h in cultures 
grown overnight under toxin-inducing conditions with 0.16 μM to 50 μM of compounds.  
C.  CT expression levels in wild type cultures grown overnight under various toxin-
inducing conditions in the presence or absence of 10 μM compounds.  The dotted line 
indicates the limit of detection.  An isogenic ΔtoxR strains served as a control.  D.  
Western blot of O395 cultures treated with 10 μM of compounds overnight in LB pH 6.5 
at 30oC, using a TcpA antibody.  E.  CT levels in cultures of RA286 grown overnight 
under toxin-inducing conditions in the presence or absence of 10 μM compounds.  Error 
bars represent the standard deviation of three biological replicates.  The dotted line 
indicates the limit of detection. 
 55 
If these compounds indeed inhibit toxT expression as opposed to altering GFP 
function, compound treatment should lead to decreased expression of ToxT-activated 
genes such as CT and TCP.  Additionally, for these compounds to have therapeutic 
potential, they should work in both classical and El Tor biotypes of V. cholerae, and 
should work in various toxin-inducing growth conditions.  CT levels were determined in 
both classical and El Tor biotypes under various in vitro conditions known to induce the 
ToxT system for each of the two biotypes.  For the classical strain O395, cultures were 
incubated overnight with 10 μM of each compound in either LB pH 6.5 at 30°C, or in 
minimal media supplemented with amino acids asparagine, glutamate, arginine and 
serine (NERS).  For the El Tor strain E7946, cultures were incubated with 10 μM of 
each compound under AKI conditions (Figure 2.2C).  Toxtazins A, B, and B’ significantly 
inhibited CT production in both biotypes and in all three tested growth conditions, 
validating the target of the compounds as toxT transcription and ruling out trivial effects, 
such as inhibition of GFP activity.  These results also indicate that the compounds are 
not biotype- or condition-specific inhibitors, though toxtazin B is more effective against 
the classical biotype.  We note that toxtazin A (but not toxtazin B or B’) completely 
inhibited growth in M9 + NERS (data not shown), indicating that toxtazin A may affect a 
pathway required for growth under these conditions, and that toxtazin A and B/B’ work 
by different mechanisms.   
O395 cultures grown overnight in LB pH 6.5 at 30°C in the presence or absence 
of compounds were also analyzed for TcpA expression by immunoblot (Figure 2.2D).  
All three compounds decreased TcpA levels relative to the DMSO-treated control, 
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supporting the conclusion that these compounds affect the virulence cascade by altering 
toxT expression.  To confirm that the compounds work on the cascade prior to toxT 
expression, we tested the effect of the toxtazins on bacteria expressing toxT ectopically, 
under control of an IPTG-inducible promoter.  We predicted that if the compounds alter 
the cascade of gene regulation that leads to toxT expression, then removing toxT 
control from that cascade would confer resistance to the effects of the compounds. 
Strain RA286, wild type expressing an IPTG-inducible allele of toxT, was cultured 
overnight under toxin-inducing conditions in either DMSO, toxtazin A, or toxtazin B, and 
toxT was induced with 100 μM IPTG.  The resulting supernatants were analyzed by 
ELISA to quantify CT levels (Figure 2.2E).  Toxtazins A and B both led to decreased CT 
expression in bacteria cultured without IPTG, while CT levels were restored in bacteria 
cultured with IPTG to induce toxT transcription, indicating that both toxtazins A and B 
act upstream of toxT in the virulence cascade.  We noted that over-expression of ToxT 
in the DMSO control led to a slight decrease in CT levels.  While the mechanism for this 
is unclear, we have observed that overexpressing components of this regulatory 
cascade (including ToxR and TcpP) can have a slight inhibitory effect on CT, perhaps 
due to altered stoichiometry of activator complexes required for gene expression.  This 
observation notwithstanding, that ectopic ToxT expression restores CT expression in 




Toxtazin B, but not toxtazin A, decreases V. cholerae colonization in an infant mouse 
model 
Host colonization by V. cholerae is dependent on TCP expression.  Based on our 
in vitro findings that the toxtazins decrease TcpA levels, we hypothesized that they 
could decrease the colonization of V. cholerae in a mouse model of colonization.  To 
test toxtazin A activity in vivo, 4-6 day old mice were orogastrically inoculated with 106 
bacteria and either toxtazin A or DMSO, and received a boost of compound three hours 
post-infection.  Because not all the compound administered will reach the desired 
location within the mouse (i.e. the small intestine), and because some of the compound 
may be processed within the mouse, we used higher concentrations of compounds in 
these experiments.  To ensure that any observed decreases in colonization are due to 
inhibition of TcpA and not to toxicity against V. cholerae, three mL LB cultures were 
started using the same inoculum and boosted with compound three hours later, then 
cultured overnight.  Administration of either 20 μg, 40 μg, or 60 μg toxtazin A to mice 
inoculated with V. cholerae did not decrease colonization levels relative to the DMSO-
treated mice (Figure 2.3A).  While toxtazin A did not reduce colonization even at the 
highest level tested, that concentration was toxic to V. cholerae grown in vitro (Figure 
2.3B).  We note that cultures grown in sub-lethal concentrations of toxtazin A routinely 
grow better in LB, and this was also seen in the in vitro experiment at 20 μg and 40 μg 
(Figure 2.3B).  The mouse data indicated that toxtazin A was not toxic in vivo at 60 μg, 
but higher doses were not tested because it would be impossible to distinguish whether 
a decrease in colonization resulted from the ability of toxtazin A to inhibit ToxT activity or 
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from its antibacterial activity.  The lack of in vivo killing by toxtazin A at 60 µg may reflect 
poor bioavailability of the compound in the infant mouse.   
Because toxtazin B and B’ are structural analogs and behave similarly in all 
assays thus far, and to reduce the number of animals used, we focused on toxtazin B in 
the following experiments.  The same in vivo experiment performed with toxtazin A  
was performed with toxtazin B.  Administration of either 100 μg or 200 μg 
toxtazin B to mice inoculated with V. cholerae decreased colonization levels 
approximately 100-fold relative to the DMSO-treated mice (Figure 2.3C).  This effect 
was not due to toxtazin B toxicity against V. cholerae since the three mL in vitro cultures 
treated with toxtazin B had no growth defect compared to the DMSO-treated cultures 
(Figure 2.3D).  These results suggest that toxtazin B inhibits expression of the TcpA 
colonization determinant both in vitro and in vivo.   
 
The toxtazins do not affect ToxR protein levels or activity. 
To determine where in the regulatory cascade leading to toxT expression each 
compound works, a targeted approach was used.  We first tested whether the 
compounds altered levels or activity of ToxR, one of the direct transcription activators of 
toxT.  ToxR protein levels were unaffected by toxtazins A, B, and B’ in cultures grown 
overnight under toxin-inducing conditions (Figure 2.4A).  ToxR activity was investigated 
by measuring levels of OmpU and OmpT, outer membrane proteins whose transcription 
is activated or repressed, respectively, by ToxR.  Inhibiting ToxR activity would 
decrease OmpU levels and elevate OmpT levels, similar to a toxR mutant.  Cell lysates
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Figure 2.3 Toxtazin B reduces V. cholerae colonization in an infant mouse. 
A. Number of V. cholerae recovered from mice orogastrically inoculated with 106 
wild type V. cholerae and treated with either DMSO, 0, 20 μg, 40 μg, or 60 μg toxtazin A.  
B.  Number of V. cholerae recovered from three mL cultures grown overnight with the 
same inocula and boosts as the mice.  C.  Number of V. cholerae recovered from mice 
orogastrically inoculated as in 3A and treated with DMSO, 100 μg or 200 μg toxtazin B.  
D. Number of V. cholerae recovered from three mL cultures grown overnight with the 
same inocula and boosts as the mice.  Asterisks denote the statistical significance of a 
group relative to the DMSO control. NS = not significant, one asterisk = p-value < 0.05, 






Figure 2.4 Effects of toxtazin A and B on the virulence cascade.  
A.  ToxR Western of cultures grown overnight under toxin-inducing conditions 
with or without 10 μM compounds.  B. Coomassie showing OmpU and OmpT levels in 
cultures grown as in 4A.  C. TcpP Western of cultures grown in the same way as in 
Figure 2.4A.  D. Transcript levels of toxT, tcpP, aphA, and aphB were determined for 
cultures grown overnight under toxin-inducing conditions in the presence or absence of 
10 μM toxtazin B. Significance was calculated by two-way ANOVA. NS = not significant, 
one asterisk = p-value < 0.05, two asterisks = p-value < 0.01, and four asterisks = p-
value <0.0001. 
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from overnight cultures grown with or without compounds under toxin-inducing 
conditions were subjected to SDS-PAGE and stained with Coomassie Blue to visualize 
OmpU and OmpT (Figure 2.4B).  Toxtazin-treated cultures have the same OmpU/OmpT 
profile as the DMSO-treated wild type culture, indicating that ToxR activity is not 
affected by toxtazin A, B, or B’.   
 
TcpP protein levels are differentially affected by toxtazin A and B/B’. 
Next, we analyzed the effect on TcpP protein levels, the other major transcription 
activator of the toxT promoter.  Cultures were grown overnight under toxin-inducing 
conditions in the presence or absence of 10 μM toxtazin A, B, or B’, and cell lysates 
were analyzed by Western blot with antiserum directed against TcpP.  Toxtazin A did 
not alter TcpP protein levels, however toxtazins B and B’ caused significant decreases 
in TcpP protein levels relative to the DMSO control (Figure 2.4C).  These results confirm 
that toxtazin A and B/B’ have different targets and mechanisms of action for inhibiting 
toxT transcription in V. cholerae.  Toxtazin B and B’ inhibit TcpP expression, while 
toxtazin A affects toxT expression without altering TcpP levels. 
 
Toxtazin B reduces transcript levels of toxT and tcpP but not of aphA or aphB. 
Because toxtazin B and B’ behave similarly, we again focused on toxtazin B for 
the next set experiments.  To determine where in the TcpP branch of the regulatory 
cascade toxtazin B acts, qRT-PCR was used to quantify the levels of toxT, tcpP, aphA, 
and aphB transcript in cultures treated overnight with 10 μM toxtazin B, incubated under 
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toxin-inducing conditions (Figure 2.4D).  All results were normalized to 16s rRNA, and 
are reported as a ratio of the mRNA levels detected in toxtazin B-treated over DMSO-
treated cultures.  As expected, toxT expression was reduced by a factor of 10 in 
cultures treated with toxtazin B relative to the DMSO control.  While aphA and aphB 
transcript levels were not affected by the compound, tcpP transcript levels were 
decreased 50% compared to the DMSO controls, consistent with the decrease 
observed in TcpP protein levels.  These data indicate that toxtazin B targets tcpP 
transcription.   
 
Neither toxtazin A nor B affects AphA or AphB levels.   
Having determined that aphA and aphB mRNA levels are not altered by toxtazin 
B, we wanted to determine whether their protein levels might be affected.  Cultures 
grown overnight under toxin-inducing conditions in the presence or absence of 10 μM 
toxtazin A or B were analyzed by Western blot (Figure 2.5).  No decrease in AphA or 
AphB protein levels was observed in the presence of toxtazin B, though AphA levels 
increased in cells treated with toxtazin A.  We do not know the reason for this, but 
speculate about it in the discussion.  Nevertheless, our results indicate that the 
decrease in tcpP transcription caused by toxtazin B is not due to a decrease in AphA or 
AphB protein levels, pointing instead to the possibility that the activity of one of these 
proteins may be inhibited by this compound. Supporting this conclusion, ectopic 






Figure 2.5 Toxtazins A and B do not affect AphA or AphB protein levels. 
Western blot for AphA and AphB in samples grown overnight under toxin-
inducing conditions in the presence or absence of 10 μM toxtazins A or B.  Band 









Figure 2.1).  As predicted, AphA and AphB levels were unaltered by growth in the 
presence of toxtazin A (Figure 2.5).   
 
Discussion 
Despite the use of antibiotics and oral rehydration therapy (ORT), V. cholerae 
remains a major public health concern in much of the developing world.  The number of 
yearly cholera cases has steadily increased since 2007, and the number of fatalities has 
increased in the past year (1).  New treatment therapies that target toxin production and 
colonization by V. cholerae, either alone or in combination with current therapies, could 
be very useful in reducing the global health burden caused by this pathogen.  
In this study, a bacterial cell-based, high-throughput screen was used to identify 
and characterize three small molecules, toxtazin A, B, and B’.  All three reduce the 
virulence potential of V. cholerae in vitro and toxtazin B also reduced colonization in vivo.  
We show that all three compounds reduce CT production in both the classical and El 
Tor biotype, and reduce TcpA levels relative to a DMSO control.   
The two classes of compounds identified here work by different mechanisms.  
Toxtazin A does not alter TcpP or ToxR protein levels, suggesting that it affects toxT 
transcription via a different mechanism.  We have not ruled out the possibility that 
Toxtazin A inhibits ToxR or TcpP function, perhaps keeping one of them from physically 
binding to its site on the toxT promoter.  Both ToxR and TcpP may sense environmental 
signals and transmit the information to the cytoplasm by activation of toxT transcription.  




Supplemental Figure 2.1 Ectopic expression of AphA and AphB in toxtazin B-treated 
cells.  
A. CT levels in a strain expressing AphA ectopically, grown overnight under toxin-
inducing conditions in the presence or absence of 10 μM compound and in the 
presence or absence of one mM IPTG.  In panels A and B, error bars represent the 
standard deviation of three biological replicates.  The dotted line denotes the limit of 
detection.  B.  CT levels in a strain expressing AphB ectopically, grown as in A.
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acids have all been shown to affect toxT activation in vitro (reviewed (23-25)).  In fact, 
when ToxT was crystalized, a cis-palmitoleate was discovered in a solvent-inaccessible 
binding pocket.  The authors of this study suggest that oleic acid, another C-9 
monosaturated fatty acid, is the natural ligand for this binding pocket, as it also strongly 
regulates ToxT activity and is more abundant in bile than cis-palmitoleic acid.  Another 
study identified the bile salt taurocholate as an in vivo signal that activates the virulence 
cascade of V. cholerae in mice.  The stressed physiological state of the cell grown with 
toxtazin A revealed by proteomic analysis (data not shown) and the growth inhibitory 
phenotype we observed in minimal medium + NERS (Figure 2.2C) lead us to propose 
that toxtazin A induces a non-permissive physiological state in the cell which feeds back 
to shut off toxT transcription, and we are currently exploring this hypothesis.  We 
investigated the potential for the toxtazins to act as general redox-active compounds by 
measuring PhoA activity both in vitro and in cells treated with the toxtazins and 
observed no effect on PhoA in either case, suggesting the toxtazins do not affect the 
general redox state of the cell.  Furthermore, the compounds do not affect the BCA 
protein assay, indicating that, at the concentrations used in our experiments, these 
compounds do not act as general reducing agents. 
The mechanism for toxtazin B/B’ inhibition of virulence is more clear.  Toxtazin B 
and B’ decrease TcpP but not ToxR protein levels, and decrease the levels of toxT and 
tcpP transcript, but not those of aphA or aphB, nor do they decrease AphA or AphB 
protein levels. 
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We noticed that toxtazin A consistently caused an increase in AphA protein levels.  
While this does not explain the anti-virulence properties of toxtazin A, it may point to its 
mechanism of action.  AphA is known to regulate 15 genes outside of the vibrio 
pathogenicity island, including genes required for acetoin biosynthesis, and two signal 
transduction proteins that influence motility and biofilm formation (26).  It is possible that 
toxtazin A affects one of these pathways, and therefore induces AphA expression. 
  Taken together, the data suggest that toxtazin B inhibits the virulence cascade 
at the level of the tcpP promoter- downstream of AphA and AphB protein production, but 
upstream of tcpP transcription.  Supporting this, ectopic expression of either AphA or 
AphB does not restore CT production (Figures 2.5B and 2.5C) in the presence of 
toxtazin B. 
Toxtazin B inhibits virulence gene expression in the classical biotype more 
strongly than in the El Tor biotype.  It is notable that tcpP transcription, the level at which 
our data suggest this compound works, is regulated differently in the two biotypes.  A 
single A to G base pair difference in the tcpP promoters of the two biotypes disrupts the 
dyad symmetry of the AphB binding motif (27-29), thus AphB binds 10 times more 
strongly to the classical tcpP promoter than to the El Tor tcpP promoter (30, 31).  We 
speculate that the natural differences in tcpP regulation in classical versus El Tor may 
be responsible for the different effectiveness of toxtazin B seen in the two biotypes in 
Figure 2.2C, but further study must be done to confirm this. 
The tcpP promoter is a highly regulated feature of the complex regulatory 
cascade controlling toxT transcription, assimilating multiple signals including pH, 
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osmolarity, cAMP levels, and phosphate levels.  For example, when cells are grown at 
the non-permissive pH, a protein called PepA partially inhibits tcpP transcription in the 
classical biotype (32).  The tcpP promoter is also negatively regulated by the cAMP-
CRP complex, whose binding site at the promoter overlaps the binding sites of AphA 
and AphB (29).  Finally, the tcpP promoter is negatively regulated by PhoB, which binds 
at a site distinct of both the AphA and AphB binding sites (33).  Toxtazin B may inhibit 
tcpP expression by altering the binding properties of any these proteins, or of the AphA 
and/or AphB proteins, at the tcpP promoter.  Future work will aim to determine the 
precise mechanism by which toxtazin B inhibits gene expression required for 
colonization and pathogenicity. 
In this study, the activity of the toxtazins in vivo was also determined using the 
infant mouse model of colonization.  The ability of V. cholerae to colonize and replicate 
in this mammalian host is in large part dependent on expression of TCP, the major 
subunit of which is TcpA; wild type strains are significantly more competitive than tcpA 
mutants in vivo (34, 35).  Our in vitro results (Figure 2.2B) demonstrate that toxtazin B 
leads to reduced TcpA levels, which we propose as the main reason for reduced 
colonization caused by toxtazin B.  We note that a tcpA mutant colonizes more poorly 
than a toxtazin B-treated wild type, and take this to mean that the local compound 
concentration (that is, the amount of toxtazin B that actually reaches V. cholerae in the 
gut) is lower than what would be require for complete inhibition.  Pharmacodynamic and 
pharmacokinetic studies might optimize the ability of toxtazin B to inhibit colonization.   
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Unlike toxtazin B, toxtazin A did not decrease colonization level of V. cholerae at 
the concentrations tested.  Perhaps this compound does not inhibit colonization 
because it does not reduce TcpA levels as efficiently as toxtazin B, or perhaps not 
enough compound reached the bacteria in the gut.  Structure-activity relationship (SAR) 
studies to identify an analog with increased potency and lower toxicity would be useful 
in future in vivo studies and for determining whether toxtazin A decreases colonization.   
In summary, we identified two novel classes of toxT transcription inhibitors, 
toxtazin A, and toxtazin B and B’.  These compounds are potent inhibitors of V. cholerae 
virulence and function at unique points in the virulence cascade (see Figure 2.6).  
Toxtazin A inhibits the virulence cascade by preventing toxT transcription late in the 
regulatory cascade, evidenced by the fact that ToxR and TcpP protein levels are equal 
to those of DMSO-treated cultures, and that mRNA levels of tcpP, aphA, and aphB are 
not affected.  Toxtazin B works by altering tcpP transcription, shown by a decrease in 
both transcript and protein levels of tcpP but no decrease in the protein or transcript 
levels of AphA or AphB relative to the DMSO-treated controls.  Toxtazin B also reduces 
colonization of V. cholerae in an infant mice model.  We are currently working on better 
characterizing the mechanism of action of the toxtazins to gain deeper insight into the 
requirements of V. cholerae pathogenesis.  In addition to providing new chemical 
probes for richer study of the virulence cascade in V. cholerae, the toxtazins add further 
proof-of-principle that potent small molecule inhibitors can be discovered by high 
throughput screening and can be used both as molecular probes for basic research and 




Figure 2.6 Model of the virulence cascade in V. cholerae and targets of the toxtazins. 
The virulence cascade in V. cholerae is tightly regulated.  AphA and AphB 
activate transcription of tcpPH.  TcpPH form an inner membrane complex with ToxR 
and ToxS to activate transcription of toxT.  ToxT activates the transcription of the tcpA-F 
operon, which encodes the toxin co-regulated pilus, and the ctxAB operon, which 
encodes the cholera toxin subunits.  Based on our experiments, we propose that 
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Materials and Methods 
Bacterial strains, growth conditions, and chemical inhibitors 
The strains and plasmids used in this study are outlined in Table 2.1.  Unless 
otherwise noted, the V. cholerae classical biotype strain O395 was used in these 
studies.  Strains were maintained at -80°C in Luria-Bertani broth (LB) containing 20% 
glycerol.  Overnight cultures were grown in LB medium at 37°C.  Growth of the O395 
classical strain under toxin-inducing conditions consists of sub-culturing an overnight 
culture 1:100 in LB pH 6.5 and growing at 30°C shaking for 16-18 h, or as indicated in 
the text.  Growth in minimal medium consists of sub-culturing an overnight culture 1:100 
in M9 minimal medium + NERS (M9 salts, 2 mM MgSO4, 4% glycerol, 0.1 mM CaCl2, 
and 5 mM each of asparagine, glutamic acid, arginine, and serine) and growing 
overnight at 37°C shaking (36).  Growth in AKI conditions consist of diluting overnights 





Table 2.1.  Strains and plasmids used in this study. 
Strain or plasmid Relevant genotype or phenotype Source 
 Vibrio cholerae  
O395 Classical Ogawa, SmR Laboratory collection 
E7946 El Tor, SmR Laboratory collection 
RA25 O395 ΔtoxR (4) 
RA6 E7946 ΔtoxR This work 
NB39 O395 + ptoxT-GFP Laboratory collection 
NB40 O395 ΔtoxR + ptoxT-GFP Laboratory collection 
RA179 O395 ΔtoxT (37) 
RA67 O395 ΔtcpP (38) 
RA305 O395 ΔaphA This work 
RA282 O395 ΔaphB This work 
RA286 O395 + pMT5 (39) 
RA289 O395 + pMMB66EH-aphA This work 
RA290 O395 + pMMB66EH-aphB This work 
RA306 O395 ΔaphA + pMMB66EH This work 
RA307 O395 ΔaphA + pMMB66EH-aphA This work 
RA308 O395 ΔaphB + pMMB66EH This work 
RA309 O395 ΔaphB + pMMB66EH-aphB This work 
 Plasmids  
ptoxT-GFP pBH6119-toxTpro-gfp This work 
pMT5 pMMB66HE-toxT (39) 
pWM91-ΔaphA pWM91-ΔaphA (40) 
pWM91-ΔaphB pWM91-ΔaphB (40) 
pMMB66EH-aphA pMMB66EH-aphA (O395 sequence) This work 
pMMB66EH-aphA pMMB66EH-aphA (O395 sequence) This work 
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for four hours statically at 37°C, then pouring the 10 mL cultures into 250 mL flasks and 
growing shaking for an additional 4 hours or longer (41, 42).   
Toxtazin A (IUPAC: 2-methanesulfonyl-4-(3-methoxyphenyl)-6-
(trifluoromethyl)pyrimidine), toxtazin B (IPUAC: 5-(4-bromophenyl)-3-(4-
methoxyphenyl)-4-(pyridin-3-yl)-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-6-one), and toxtazin 
B’ (IUPAC: 3-(4-chlorophenyl)-5-(4-methylphenyl)-4-(pyridin-3-yl)-1H,4H,5H,6H-
pyrrolo[3,4-c]pyrazol-6-one) were obtained from ChemDiv (San Diego, CA).  Compound 
stocks were made to either 20 mM or 100 mM in DMSO and stored in the dark at -20°C.  
Cultures were treated with 10 μM unless otherwise specified in the text, and the controls 
always received an equal volume of DMSO.  Streptomycin was used at 100 μg/mL, 
ampicillin at 100 μg/mL, and X-gal at 40 μg/mL. 
The screening plasmid ptoxT-gfp was created by digesting pTLI2 (43) with EcoRI 
and BamHI to generate the (-172) to (+45) toxT promoter fragment.  This fragment was 
ligated into the promoterless GFP reported vector pBH6119 (44).  The reporter plasmid 
was electroporated into wild type O395 and an isogenic ΔtoxR mutant to generate the 
screening strains. 
The E7946ΔtoxR strain was constructed using the pKAS32-ΔtoxR suicide 
plasmid as done previously (6) using wild type E7946 as the recipient.  
The clean deletions of aphA and aphB in O395 were generated by mating wild 
type O395 cells with SM10λpir cells containing either pWM91-ΔaphA or pWM91-ΔaphB 
(kindly provided by Jun Zhu) and selecting for sucrose-resistant colonies.  Mutants were 
confirmed by DNA sequencing. 
 74 
The pMMB66EH-AphA and AphB constructs were constructed by amplifying the 
AphA sequence using primers RAP186 (GCAACGAATTCATGTCATTACCA) and RAP 
187 (GTCAAGCTTTTATGCCATCGC) and the AphB sequence using primers RAP218 
(GCC GAATTCTTGCAACATAATGTGTCAGA) and RAP219 
(CCGAAGCTTTTATTGCAGGTGGTAGCC) from O395.  The resulting products were 
digested with EcoRI and HindIII and ligated into pMMB66EH.  The resulting constructs 
(Table 2.1) were verified by DNA sequencing. 
 
IC50 and EC50 determination 
The concentration of compound that inhibits toxT-GFP activity to 50% of the DMSO-
treated control (EC50) was measured by inoculating two mL of LB with a 1:100 dilution of 
an overnight culture and monitoring GFP expression under toxin-inducing conditions 
with 0.16 μM to 50 μM of compounds.  The OD600 of these cultures was also monitored 
to determine the IC50, the concentration of compound that inhibits growth to 50% of the 
DMSO-treated control.  EC50 and IC50 values were calculated in Graphpad Prism using 
the 4-parameter model (variable slope). 
 
High-throughput screening for small molecule inhibitors of toxT-gfp production 
The screening strain used (NB39) is an O395 classical strain harboring a plasmid 
with the toxT promoter driving expression of GFPmut3.  An isogenic O395 ΔtoxR strain 
with the toxT-GFP reporter (NB40) served as a control in the screen.   
The primary screen, secondary screen, and dose-response studies were carried 
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out at the Center for Chemical Genomics (University of Michigan), where approximately 
63,000 compounds and 11,000 natural products were tested. Overnight cultures of 
NB39 were diluted to a final OD600 of 0.02 in LB pH 6.5 + streptomycin and ampicillin, 
and transferred in a 40 μl volume to wells of a black, clear-bottom 384-well microtiter 
plate (Falcon 35-3948).  The screening plates received 10 μM of compounds, which 
were pin-transferred from stock plates.  Each test plate contained positive (strain NB40 
+ DMSO) and negative (strain NB39 + DMSO) controls, and all compounds were tested 
in at least duplicate.  The plates were incubated at 30°C for 16-18 hours statically, after 
which the OD600 and GFP fluorescence (excitation λ = 385 nm, emission λ = 425 nm) 
were read for each well. 
A compound was considered active if it met two criteria: i) it caused a decrease in 
GFP expression of more than six standard deviations from the DMSO control, and ii) the 
OD600 of cultures grown with the compound was within 10% of the DMSO control.  A 
total of 1,411 compounds met both criteria and were retested for their effects on growth 
and toxT-gfp expression, and their dose responsiveness.  Of the 175 compounds that 
retained activity and displayed dose-dependent activity, the 50 most potent (a low 
GFP/OD600 value) were ordered from ChemDiv and similarly retested for effects on 
growth and toxT transcription, and for effects on CT production. Of the 21 compounds 
that caused significantly reduced CT levels, we focused on toxtazins A, B, and B' 
because of their potency (Figure 2.1C).  
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Detection of cholera toxin by ELISA 
Cultures of V. cholerae were grown under toxin-inducing conditions for 16-18 
hours with 10 μM compound or DMSO. GM1 ganglioside enzyme-linked immunosorbent 
CT assays were performed as previously described (45) on equal volumes of the 
resulting supernatants. CT expression values were normalized to OD600 and are the 
average of samples grown in at least duplicate.  
 
Western blot analysis of TcpA, ToxR, TcpP, AphB, and AphA 
Cells were cultured under toxin-inducing conditions in the presence or absence of 
10 μM compounds. Cell extracts were subjected to SDS-PAGE, transferred to a 
nitrocellulose membrane (GE Water and Processes Technologies, Feasterville-Trevose, 
USA), probed with the appropriate antibody, and visualized by alkaline phosphatase. 
The TcpA antibody was used at a 1:10,000 dilution, the ToxR antibody at a 1:1,000 
dilution, and the TcpP antibody at a 1:500 dilution.  The AphB antibody was kindly 
provided by Dr. Jun Zhu. The AphA antibody (kindly provided by Dr. Karen Skorupski) 
was used at a 1:10,000 dilution.  Band densities were determined with the Image J 
software (http://rsb.info.nih.gov/ij/) and normalized to the wild-type DMSO-treated 
samples. 
 
qRT-PCR analysis of mRNA expression 
Cells were cultured under toxin-inducing conditions in the presence or absence of 
10 μM toxtazin B.  RNA was harvested with TRIzol® (Invitrogen, Carlsbad, CA) 
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according to the manufacturer directions, and DNA was removed using TURBO DNase 
(Ambion, Austin, TX).  The qRT-PCR experiments were performed using the Quantitect 
SYBR Green RT-PCR kit (Qiagen, Valencia, CA) according the manufacturer manual. 
The qRT-PCR primers are shown in Table 2.2. Expression levels were normalized to 
16s rRNA, and fold change was calculated using the 2−ΔΔCT method described in the 
Applied Biosystems User Bulletin No. 2 (P/N 4303859). Results are the average of three 
biological replicates with three replicates each.  Significance was determined by two-
way ANOVA. 
 
Infant mouse colonization assays 
Four to six day-old CD1 mice (Charles River, Wilmington, MA) were 
orogastrically inoculated with a 30 μl bolus containing 106 CFU of V. cholerae O395, 
Cremaphor EL (20% final volume to solubilize compounds), and either DMSO or 
compound (dose indicated in text). An additional 30 μl bolus lacking bacteria was 
delivered to each mouse three hours post-inoculation, and the mice were incubated at 
30°C. Mice were euthanized 18-24 hours after inoculation, the intestines were isolated, 
weighed, and homogenized in PBS.  Homogenates were serially diluted and plated on 
LB agar + X-gal + streptomycin to determine the number of CFU recovered.  CFUs were 
normalized to the weight of the intestines and to the exact CFU of the initial inoculum.  









Table 2.2 Primers used for qRT-PCR analysis. 












































































































































Mechanism of Action of Toxtazin A 
 
Summary 
Target identification is a major challenge in research on small molecule inhibitors, 
and many reviews have been written describing various approaches that have 
successfully been used (1-3).  To identify the mechanism by which toxtazin A inhibits 
toxT transcription, we combined a loss-of-target strategy, which generates and tests 
possible hypothetical mechanisms of action, with two screening approaches.  The 
results of this research suggest that toxtazin A may affect toxT transcription by inducing 
envelope, oxidative, and nutrient stress responses in the cell. 
 
Introduction 
Vibrio cholerae causes the acute and sometimes fatal diarrheal disease cholera 
by producing and secreting cholera toxin (CT) into the lumen of the host (4).  
Transcription of CT is activated by ToxT (5), expression of which is activated by ToxR 
and TcpP, two inner membrane transcriptional activators (6-10).  Two small molecule 
inhibitors of toxT transcription, toxtazin A and toxtazin B, were identified in a high-
throughput screen, and toxtazin A was found to inhibit toxT transcription and CT 
expression without affecting ToxR or TcpP expression (11). 
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Experimental evidence presented here indicates that toxtazin A treatment causes 
cells to activate stress pathways, suggesting that stress signaling may be linked to 
virulence gene regulation in V. cholerae.  While this has not been shown directly in V. 
cholerae, many bacterial pathogens alter their virulence programs in response to stress 
signals.  For example, many pathogenic bacteria activate their virulence genes in 
response to temperature stress (reviewed in (12)).  Bacteria also sense membrane 
perturbations, called envelope stress, and while the mechanisms for sensing and 
responding the envelope stress is bacteria-specific, it generally involves activating the 
alternate sigma factor E (σE), the Cpx two component system, and/or the BaeSR two 
component system, which in turn represses virulence factors (reviewed in (13)).  In V. 
cholerae, σE is required for colonization of infant mice and for growth in 3% ethanol, 
though the mechanism behind this is not clear (14). Oxidative and nitrosative stress 
responses have also been shown to be inhibit virulence gene expression in a number of 
organisms (15-18).  As is the case with envelope stress, mutants deficient in the 
oxidative or nitrosative stress responses are attenuated in animal models; however, the 
mechanism by which stresses affect pathogenesis is not fully understood.  Additionally, 
growth under nutritional stress induces the stringent response, which affects the 
activation of virulence genes in many pathogens, including V. cholerae (19, 20). 
Here, we present evidence that toxtazin A does not affect ToxR or TcpP 
localization to the inner membrane, nor does it inhibit ToxR binding to the toxT promoter.  
Toxtazin A causes a growth defect in M9 minimal media supplemented with amino acids 
asparagine, glutamate, arginine, and serine (NERS) and in LB supplemented with 3% 
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ethanol, suggesting that it can activate both nutrient and envelope stress responses in 
the cell.  Furthermore, toxtazin A induces the expression of an oxidoreductase, 
suggesting toxtazin A induces an oxidative stress response.  A comparative proteomic 
approach corroborates the above results.  Based on these findings, we hypothesize that 
toxtazin A induces stress response(s), particularly redox stresses, which in turn signals 
the cell to shut off toxT transcription.  Through this chemical biology approach, the work 
described expands our knowledge of the physiological control of virulence gene 
expression in V. cholerae.  
 
Results 
ToxR and TcpP localize correctly to the membrane 
One mechanism by which toxtazin A could inhibit toxT transcription without 
altering ToxR or TcpP levels would be by altering the localization of either or both of 
these activators, rendering them incapable forming a complex at the inner membrane.  
To address this possibility, cultures were grown overnight under toxin-inducing 
conditions in the presence or absence of 10 μM toxtazin A before collecting the cells by 
centrifugation.  Pellets were resuspended in a Tris buffer and lysed by French press 
before ultracentrifugation.  The resulting supernatants, containing the cytoplasmic and 
periplasmic proteins, and pellets, containing membranes, were diluted or resuspended 
in sample buffer and boiled prior to electrophoresis and immunoblotting with TcpP or 
ToxR antisera (Figure 3.1).  Toxtazins B and B’ were also analyzed by this approach.  






Figure 3.1 The toxtazins do not alter the membrane-localization of ToxR or TcpP 
Cells treated overnight under toxin-inducing conditions in the presence or 
absence of 10 μM toxtazin A, B, or B’ were lysed, and the membranes were separated 
from the cytoplasmic and periplasmic fractions by ultracentrifugation.  The localization of 
ToxR and TcpP was determined by Western blot analysis.  EpsL served as a control for 




was used as a control for the membrane fraction, while expression of GFP was used as 
a control for the cytoplasmic fraction.  
The GFP and EpsL results indicate that the fractionation protocol worked well, 
with 98% of GFP fluorescence identified in the soluble (cytoplasmic) fraction and all 
detectable EpsL identified in the pellet (membrane) fraction.  Treatment with 10 μM of 
any of the toxtazins did not alter membrane localization of ToxR.  Localization of TcpP 
was unaffected by toxtazin A or toxtazin B, but absolute levels of TcpP produced were 
severely decreased by toxtazin B treatment, just as previously described (Chapter 2; 
(11)).  Taken together, these results rule out a mechanism by which the toxtazins affect 
toxT gene expression by reducing membrane localization of the toxT regulators ToxR or 
TcpP.   
 
Toxtazin A does not inhibit ToxR from binding the toxT promoter 
Having eliminated the possibility of toxtazin A inducing ToxR and/or TcpP 
mislocalization, we next tested the hypothesis that it may inhibit the ability of ToxR to 
bind the toxT promoter.  Because ToxR and TcpP are single-pass inner membrane 
proteins, they are difficult to purify.  Consequently, gel shifts have been performed using 
membrane fractions of cells over-expressing either ToxR or TcpP (10).  These 
membrane fractions do not enter the gel, so complexes of protein and radiolabeled DNA 
are observed in the well, while non-complexed radiolabeled DNA is detectable within the 
gel proper.   
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Membrane fractions from cells lacking ToxR or with plasmid-expressed ToxR 
were isolated by ultracentrifugation.  Varying amounts were incubated with radiolabelled 
toxT promoter and either 50μM toxtazin A in DMSO, or DMSO alone for 30 minutes at 
30°C, after which the reaction mixture was subjected to electrophoresis through a 6% 
polyacrylamide gel.  Radiolabeled toxT promoter was shifted by ToxR at membrane 
concentrations of 0.5 mg/ml or greater, but was not shifted by membranes from cells 
lacking ToxR.  When 50 μM toxtazin A was added, ToxR still bound and shifted the toxT 
promoter, and the concentration at which this occurs was not altered, even at a 
concentration of toxtazin A five times greater than what we demonstrated is effective for 
reducing toxT expression (Figure 3.2).  These results indicate that in vitro, toxtazin A 
does not inhibit the ability of ToxR to bind the toxT promoter, nor does it affect the 
amount of ToxR required for binding.  
 
Toxtazin A confers growth defects under some conditions 
Two observations suggest that toxtazin A may directly or indirectly affect central 
metabolism.  One is that cultures grown at 30°C in M9 minimal media supplemented 
with asparagine, glutamate, arginine, and serine (NERS) – a condition known to 
stimulate toxin and pilus production – demonstrated a growth defect when toxtazin A 
was added (Figure 3.3).  This was not observed when toxtazin B or B’ was added, 
indicating that this phenomenon is specific to toxtazin A.  This growth defect was more 
severe in the classical O395 strain than in the El Tor C6706 strain, indicating this effect 







Figure 3.2 Toxtazin A does not inhibit ToxR from binding the toxT promoter 
Membranes were purified from V. cholerae ΔtoxR containing pSK empty vector 
or pSK-ToxR-HA.  Varying concentrations of membranes were incubated with 
radiolabeled toxT probe in the presence or absence of toxtazin A, then run on a 6% 
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Envelope stress response and toxtazin A 
Gram-negative bacteria respond to envelope stress by activating σE, encoded by 
the rpoE gene (13).  RpoE is essential for responding to membrane stress and is 
important for virulence, as an rpoE mutant is 30-fold decreased for colonization of infant 
mice (14).  It was previously shown that wild type V. cholerae can grow in LB + 3% 
ethanol, which induces envelope stress, while an rpoE mutant cannot (14).  To 
determine if toxtazin A affects the ability of cells to sense and/or respond to envelope 
stress, cultures were grown in the presence and absence of 10 μM toxtazin A in LB + 
3% ethanol at 37°C.  An rpoE mutant served as a positive control.  As shown in Figure 
3.4, 10 μM toxtazin A prevented wild-type cells from growing in LB + 3% ethanol at 
37°C to levels similar as that of an rpoE mutant.  This was specific to toxtazin A, as 
toxtazin B showed only a mild growth defect.  
It remains unclear why toxtazin A causes growth defects in some media (M9 minimal 
media + NERS and in LB + 3% ethanol), but not in others (LB and AKI medium).  We 
hypothesize that cells grown in minimal media or in 3% ethanol undergo stress(es) that 
they do not encounter in rich media.  Response to these stresses is required for wild 
type growth and we further hypothesize that toxtazin A blocks a key stress response 
mechanism.  If this is true, it would suggest a link, whether direct or indirect, between 
cellular stress and virulence, and would uncover another level of regulation to the 









Figure 3.3 Toxtazin A causes a growth defect in M9 + NERS 
Cultures of O395 or C6706 grown for 16 hours in M9 + NERS at 30°C are 








Figure 3.4. Toxtazin A inhibits growth in LB + 3% ethanol  
Cultures of O395 were grown for 16 hours in LB + 3% ethanol in a 96-well plate 
at 37°C in the presence of either DMSO, 10 μM toxtazin A, or 10 μM toxtazin B, and the 




















A proteomic approach toward MOA identification 
In combination with the approaches described above, we sought to determine the 
mechanism of action of toxtazin A using an unbiased approach.  To characterize effects 
of toxtazin A on O395 V. cholerae grown overnight under toxin-inducing conditions (LB 
pH 6.5 at  30°C shaking), we subjected protein extracts of these cells to gel LC-MS/MS.  
Proteins were collected from cell lysates by TCA precipitation and subjected to SDS-
PAGE.  Twenty sequential gel slices were digested with trypsin followed by analysis 
with tandem mass-spectrometry to generate a semi-quantitative list of proteins present 
in the sample. 
We focused our initial analysis on proteins with a four-fold difference in quantity 
between extracts from DMSO- versus toxtazin A-treated samples (indicating the protein 
is more highly expressed in one sample than the other), excluding ~700 proteins that 
were detected 10 times or fewer in both samples to increase confidence (Table 3.1).  
Known ToxT-controlled proteins are marked by an asterisk in Table 3.1, and account for 
19.4% of the proteins identified.  These proteins were expected to be diminished by 
toxtazin A because of its effects on toxT transcription.  In contrast, no AphA- or AphB-
regulated proteins (21, 22) were differentially expressed in the presence of toxtazin A, 
corroborating the finding that AphA and AphB are not affected by toxtazin A.  That 
ToxT-dependent proteins are so prevalent in these data while no AphA- or AphB-
dependent proteins were identified suggests that this method of identifying proteins 
affected by toxtazin A is reliable.   
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Table 3.1 Proteins with 4-fold differential expression in toxtazin A-treated cells.   








Malate&synthase&& VCA0957& 13& 0& #DIV/0!& Metabolic&process& Malate&synthase&activity&
Oye&family&NADHEdependent&flavin&




flavoprotein&alphaEcomponent&& VC_0384& 14& 0& #DIV/0!& Cysteine&biosynthesis& Oxidoreductase&
Sulfite&reductase&subunit&beta&& VC_0385& 12& 0& #DIV/0!& Cysteine&biosynthesis& Oxidoreductase&





Superoxide&dismutase,&CuEZn&& VC_1583& 19& 0& #DIV/0!&
Cell&redox&
homeostasis& Superoxide&dismutase&activity&




methylthiotransferase&& VC_2620& 13& 0& #DIV/0!& RNA&processes& Transferase&activity&
Peroxiredoxin&family&










Enterobactin&receptor&protein&irgA& VC_0475& 17& 2& 8.50& Pathogenesis& Transporter&activity&
Thiosulfate&ABC&transporter&





















dusA& VC_0379& 11& 2& 5.50& tRNA&processing&
Flavin&adenine&dinucleotide&
binding&
Protease&& VC_0717& 16& 3& 5.33& Proteolysis& Peptidase&activity&




substrateEbinding&protein&& VC_0010& 55& 12& 4.58& Amino&acid&transport& Transporter&activity&










protein& VC_A0978& 4& 16& 0.25& Amino&acid&transport& Transporter&activity&
Chemotaxis&protein&CheV&& VC_2006& 3& 12& 0.25& Chemotaxis& Signal&transducer&activity&
TranscriptionErepair&coupling&
factor&& VC_1886& 13& 53& 0.25& DNA&processes&
ATPEdependent&helicase&
activity&
Hypothetical&protein&VC1645&& VC_1645& 3& 13& 0.23& Metabolic&process& Hydrolase&activity&
Septum&siteEdetermining&protein&
MinD&& VC_1960& 3& 13& 0.23& Cytokinesis& ATPase&activity&
MarR&family&transcriptional&




AcfC&& VC_0841& 20& 104& 0.19& Pathogenesis& Pilus&
Amino&acid&ABC&transporter&
substrateEbinding&protein&& VC_1362& 2& 11& 0.18& Amino&acid&transport& Transporter&activity&
Zinc/cadmium/mercury/leadE
transporting&ATPase&& VC_1033& 29& 173& 0.17& Metal&ion&transport&
CationEtransporting&ATPase&
activity&
Aldehyde&dehydrogenase&& VC_1819& 8& 48& 0.17&
Cell&redox&
homeostasis& Oxidoreductase&
Hypothetical&protein&VCA0271&& VC_A0271& 4& 24& 0.17& Unknown& DNA&binding&









ATPEdependent&RNA&helicase&RhlB&& VC_0305& 2& 12& 0.17& RNA&processes&
ATPEdependent&RNA&helicase&
activity&





Hypothetical&protein&VC1249&& VC_1249& 12& 85& 0.14& Unknown& Unknown&
Exonuclease&V&subunit&gamma&& VC_2322& 3& 23& 0.13& DNA&processes&
Exodeoxyribonuclease&V&
activity&
Hypothetical&protein&VC1083&& VC_1083& 2& 17& 0.12& Unknown& Hydrolase&activity&
Sensory&box&sensor&histidine&












DnaE& VC_2245& 3& 36& 0.08& DNA&processes& 3'E5'&exonuclease&activity&
Porin&& VC_0972& 2& 29& 0.07& Transport& Porin&activity&
*&Cholera&enterotoxin&subunit&A&& VC_1457& 5& 115& 0.04& Pathogenesis& Toxin&
*&Toxin&coEregulated&pilus&
biosynthesis&protein&S&& VC_0834& 0& 58& 0.00& Pathogenesis& Pilus&assembly&
*&Accessory&colonization&factor&
AcfA&& VC_0844& 0& 56& 0.00& Pathogenesis& Colonization&
*&Toxin&coEregulated&pilus&
biosynthesis&outer&membrane&
protein&C&& VC_0831& 0& 46& 0.00& Pathogenesis& Pilus&assembly&
*&Toxin&coEregulated&pilus&
biosynthesis&protein&B&& VC_0829& 0& 37& 0.00& Pathogenesis& Pilus&assembly&
*&ToxREactivated&gene&A&protein&




biosynthesis&protein&D&& VC_0833& 0& 33& 0.00& Pathogenesis& Pilus&assembly&














AcfB&& VC_0840& 0& 19& 0.00& Pathogenesis& Signal&transducer&activity&
Hypothetical&protein&VC0414&& VC_0414& 0& 17& 0.00& Unknown& Unknown&
*&Toxin&coEregulated&pilus&
biosynthesis&protein&E&& VC_0836& 0& 17& 0.00& Pathogenesis& Protein&secretion&
Protease&& VC_A0223& 0& 16& 0.00& Proteolysis& Metallopeptidase&activity&
Hypothetical&protein&VCA0574&& VC_A0574& 0& 14& 0.00& Unknown& NEacetyltransferase&activity&




TrpA& VC_1169& 0& 13& 0.00&
AminoEacid&
biosynthesis& Tryptophan&synthase&activity&
Cholera&enterotoxin&subunit&B&& VC_1456& 0& 12& 0.00& Pathogenesis& Toxin&
Hypothetical&protein&VC2507&& VC_2507& 0& 12& 0.00& Unknown& ATP&binding&
Cytochrome&b561,&putative& VC_A0249& 0& 11& 0.00& Respiration& Electron&carrier&activity&
Hypothetical&protein&VCA1024&& VCA1024& 0& 11& 0.00& Unknown& Unknown&
Toxin&coEregulated&pilus&







Figure 3.5 GO terms of proteins differentially expressed in the presence of toxtazin A. 
Cultures of O395 V. cholerae were grown for 16 hours in the presence or 
absence of toxtazin A.  Cells were pelleted, washed twice in PBS, and lysed.  The 
proteins were separated by SDS-PAGE, trypsin digested, and the peptides were 
identified by liquid chromatography and tandem mass spectrometry (gel LC-MS/MS).  
The proteins that were four-fold differentially produced in the toxtazin A-treated cells, 
and detected at least 10 times or more in each sample.  These pie charts indicate the 
GO terms that are differentially more highly produced in DMSO-treated cells (left pie 
chart) or in toxtazin A-treated cells (right pie chart).  
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Genome ontology (GO) terms were used to classify proteins altered by toxtazin A (Table 
3.1; Figure 3.5).  The largest category is pathogenesis, followed by proteins of unknown 
function.  The next largest group represents proteins involved in cell redox homeostasis, 
which strengthens our hypothesis that toxtazin A-treated cells are experiencing and 
responding to stress.  For example, the peroxiredoxin family protein PrxA (VC2637) was 
identified often (59 times) and exclusively in toxtazin A-treated cells.  This protein is 
regulated by OxyR and is important for responding to H2O2 stress (23), and is required 
for infant mouse colonization by V. cholerae (24).  That cells grown in the presence of 
toxtazin A activate OxyR-dependent genes suggests that they may be sensing and/or 
responding to oxidative stress or ROS.   
 
Oxidoreductase VC0731 is induced by toxtazin A 
The gel LC-MS/MS results indicated that six oxidoreductases (9.7% of the 
differentially expressed proteins) are differentially expressed in cells treated with 
toxtazin A.  A seventh, VC0731, was also induced in toxtazin A-treated cells, though it 
was not recovered enough times to make the cutoff for confidence in the gel LC-MS/MS 
experiment.  Rather, it was identified as a ~27 kDa band on coomassie-stained, one-
dimensional SDS-PAGE gels that as consistently more expressed in toxtazin A-treated 
cells (Figure 3.6A).  Mass spectrometry analysis determined this band to be VC0731, 
annotated as an AhpC-like oxidoreductase.  Two toxtazin A analogs, toxtazins A2 and 
A3 that also reduced toxT-GFP levels, also induced VC0731 expression (Figure 3.6B), 




Figure 3.6 Toxtazin A treatment results in overexpression of VC0731. 
Cultures were grown under toxin-inducing conditions (LB pH 6.5 at 30°C) for 16 
hours in the presence or absence of 10 μM of various compounds.  Cells were pelleted, 
lysed, and resuspended in sample buffer, normalizing for OD600, then run on a 12.5% 
SDS-PAGE gel.  The gel was stained with Coomassie to visualize VC0731.  A.  O395 
cultures were grown with DMSO, toxtazins A, B, or B’.  B.  Reporter strain RA2 (O395 + 
ptoxT-gfp) cultures were grown with toxtazin A, or analogs A2 and A3.  C.  Cultures of 
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pharmacocore.  VC0731 was induced by toxtazin A in both classical (O395) and El Tor 
(N16961) biotypes and irrespective of toxT, toxR, and tcpP (Figure 3.6C). 
Because AhpC is regulated by OxyR in E. coli (25), we sought to determine 
whether VC0731, an AhpC-like protein, might also be regulated by OxyR.  We grew an 
oxyR::TnFGL3 insertion mutant (from a previously described ordered transposon library 
(26)) in the presence or absence of 10 μM toxtazin A overnight under toxin-inducing 
conditions.  Extracts were analyzed by SDS-PAGE.  The gene upstream of and 
divergently transcribed from VC0731, VC0732, is annotated as a LysR-family regulator.  
Because these regulators often control genes from which they are divergently 
transcribed (27), we also tested a strain carrying a transposon insertion in VC0732.  The 
results indicate that expression of VC0731 requires VC0732, but not OxyR (Figure 3.7A).  
Further, its expression is elevated by growth at 37°C regardless of toxtazin A treatment 
(Figure 3.7B). 
We hypothesized that over-expression of VC0731 caused by toxtazin A could 
inhibit toxT gene expression, thereby limiting toxin and pilus production.  To test this, we 
ectopically expressed VC0731 on an arabinose-inducible plasmid in V. cholerae cells 
grown overnight under toxin-inducing conditions.  Culture supernatants were then 
examined for CT levels by CT ELISA.  Contrary to our hypothesis, overexpression of 
VC0731 per se does not lead to decreased CT expression (Figure 3.8A).   
We also tested whether VC0732, the LysR-activator that controls VC0731 
expression, regulates proteins that might inhibit CT expression.  A mutant lacking 







Figure 3.7 VC0731 is activated by VC0732, not OxyR, and is induced at 37°C. 
A.  Wild-type, Tn-oxyR, and Tn-VC0732 C6706 strains were grown for 16 hours 
under AKI conditions, which induces virulence gene expression in the El Tor biotype.  
Cell extracts were run out on a 12.5% SDS-PAGE gel and VC0731 was visualized by 
Coomassie staining.  B. Wild-type O395 cultures were grown in LB at 37°C or in LB pH 
6.5 at 30°C, which induces virulence gene expression in the Classical biotype.  VC0731 
was visualized by coomassie staining. 
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Figure 3.8.  VC0731 and VC0732 do not affect CT expression. 
A. Cultures of wild-type O395 containing arabinose-inducible pAD18-
VC0731were grown for 16 hours under toxin-inducing conditions.  Supernatants were 
collected and analyzed for CT levels by ELISA.  B. Wild-type O395 and an isogenic 
ΔVC0732 mutant were grown for 16 hours under toxin-inducing conditions (LB pH 6.5 at 
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similar in wild type and Δvc0732 cells, ruling out any action on toxin production by the 
toxtazins that works through a VC0732-dependent mechanism (Figure 3.8B). 
These results indicate that toxtazin A does not reduce CT expression by 
controlling VC0731 or VC0732.  However, they do clearly suggest that toxtazin A 
causes the cell to sense or respond to oxidative stress, which is associated with an 
inability of bacteria to activate toxT and leading to down-regulation of toxin and pilus 
production.   
 
Screening for toxtazin A-resistant mutants  
Using an open-ended approach to identify the mechanism of action of toxtazin A, 
we developed a screen for mutants that could no longer respond to toxtazin A.  We 
reasoned that a mutation in the toxtazin A target would render strains non-responsive to 
the compound, resulting in elevated toxT expression in the presence of toxtazin A.  
Libraries of both transposon-induced mutants and potential spontaneous mutants 
generated by continuous cycles of growth over several generations were tested.  For 
the transposon screen, a mariner-based transposon conferring kanamycin resistance 
was introduced into the original ptoxTpro-gfp reporter strain used to identify toxtazin A.  
Transposons were collected and pooled.  Generation of spontaneous mutants was 
achieved by growing the reporter strain for 30 days with daily 1:100 dilutions.   
To identify mutants resistant to either of the toxtazins, the transposon libraries 
were grown for 16 hours under toxin-inducing conditions (LB pH 6.5 at 30°C shaking) in 
the presence of DMSO, 50 μM toxtazin A, or 10 μM toxtazin B.  The mutant libraries 
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grew similarly in the presence or absence of the toxtazins, and GFP levels decreased in 
the presence of either toxtazin A or B, indicating that the majority of mutants in the 
transposon libraries are sensitive to toxtazins A and B (Figure 3.9A and B).  Cultures 
were then subjected to sorting by FACS (Figure 3.9C) to identify individual cells with 
elevated GFP levels in the presence of either toxtazin A or B.  GFP levels of DMSO-
treated cultures fit a single peak instead of displaying a bimodal distribution, indicating 
that the earlier GFP readings represent an average of GFP expression per cell, not an 
average of a population of cells expressing little GFP while and others expressing 
higher GFP.  Treatment with either of the toxtazins followed this same trend but the 
GFP peak was shifted down, indicating that most of the mutants were still sensitive to 
treatment with either of the toxtazins, and any mutants resistant to toxtazin A or B 
treatment are rare, with no selective advantage in our growth conditions.   
Toxtazin A-treated and toxtazin B-treated cells in the top 5% for GFP expression 
were sorted, and those that were in the top 1% for GFP expression were excluded to 
eliminate dead cells.  The sorted cells, plated for isolation, were cultured in 96-well 
plates and frozen into glycerol stocks.  Unfortunately, when the strains isolated as GFP-
high in the presence of toxtazin A were retested in the presence of toxtazin A, they had 
low toxT-GFP levels indicating that were no longer resistant to toxtazin A.  The same 
was true when the toxtazin B-resistant mutants were re-tested against toxtazin B.  The 
reason for this remains unclear, but it is possible that the strains isolated by FACS 




Figure 3.9 FACS sorting of transposon mutants for resistance to toxtazins A or B. 
The OD600 (A) and GFP (B) levels of transposon mutant libraries grown overnight 
under toxin-inducing conditions in the presence or absence of the toxtazins.  C. FACS 
analysis of the transposon libraries.  Wild-type O395 was used to define the GFP-lo pool 
as it does not express GFP.  The mutant strains contained the toxT-GFP reporter, and 
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The purpose of this work was to characterize the mechanism of action of toxtazin 
A, which was originally identified for its ability to inhibit transcription of toxT (11).  
Different hypotheses were examined including i) whether toxtazin A affects ToxR or 
TcpP, the transcriptional activators of toxT, and ii) whether cellular stresses, many of 
which are induced in the presence of toxtazin A, may regulate toxT.  
Toxtazin A did not inhibit ToxR or TcpP from correctly localizing to the membrane, 
nor did it inhibit ToxR from binding the toxT promoter as shown by gel shift assays; 
however, this does not eliminate the possibility that a more complex mechanism may 
occur in vivo.  For example, toxtazin A may stabilize or otherwise promote inhibition of 
ToxR binding through a molecule not present in these membrane fractions.  This 
hypothesis could be tested by chromatin immunoprecipitation to determine toxT 
promoter occupancy by ToxR in cells treated or not treated with toxtazin A.  
Experiments also are being carried out to determine whether toxtazin A inhibits TcpP 
from binding the toxT promoter, and to determine whether ToxR-TcpP interaction is 
inhibited by toxtazin A treatment.   
It was also found that toxtazin A-treated cells grew poorly or not at all under 
certain stress-inducing conditions (minimal media + NERS and LB + 3% ethanol) 
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suggests that toxtazin A affects one or more stress responses.  Supporting this 
hypothesis is the observation that toxtazin A-treated cells up- or down-regulated 
expression of many proteins involved in stress pathways, including cell redox 
homeostasis and amino acid transport and biosynthesis.  Experiments on VC0731 and 
its regulator VC0732, however, indicate that this pair of oxidoreductase and regulator 
does not inhibit the virulence cascade. 
Identification of resistant mutants by FACS sorting has been successfully used by 
others (28, 29); however, we were not able to select toxtazin A- or B-resistant mutants 
with this technique.  This approach could be improved by growing the GFP-high cells in 
the presence of toxtazin A or B and repeating the FACS sorting multiple times to enrich 
for resistant mutants.  This enrichment step was necessary for the isolation of 
enzalutamide-resistant cells (30).  Alternatively, a selective approach could be used to 
select for toxtazin A-resistant mutants using the growth defects in either LB + 3% 
ethanol or M9 minimal media supplemented with NERS.  Mutants able to grow in the 
presence of toxtazin A under these stress conditions may be resistant to toxtazin A-
dependent inhibition of toxT, and may therefore pinpoint the target of toxtazin A.  One 
caveat to this experiment is that the growth arrest target may be different from the 
pathogenesis target. 
Toxtazin A has been screened in 4 BioAssays in PubChem, and 29 toxtazin A 
analogs have been screened in BioAssays.  In these BioAssays, micromolar levels of 
toxtazin A as well as toxtazin A analogs were found to inhibit the anti-apoptotic protein 
Bfl-1 (gene bcl2a1a of Mus musculus) (31).  Other toxtazin A analogs were identified as 
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positive in 20 BioAssays reported in PubChem.  Of those, the effects of the toxtazin A 
analogs were confirmed in secondary assays and shown to behave in a dose-
dependent manner for the inhibition of NOD1 and NOD2, inhibition of peroxiredoxins in 
Schistosoma mansoni, and the inhibition of the mammalian selenoprotein thioredoxin 
reductase 1 (TrxR1). 
The data presented here generate several new hypotheses about virulence gene 
regulation in V. cholerae.  First, the observation that toxtazin A affects cellular stress 
pathways and reduces toxT expression prompted the hypothesis that one or more 
cellular stress responses can feedback to inhibit virulence gene expression.  This 
hypothesis is exciting because it would be the first demonstration of cellular stress 
regulating virulence in V. cholerae.  Furthermore, the fact that in the presence of 
toxtazin A, ToxR and TcpP are both present at wild-type levels and localized to the 
membrane yet do not activate toxT transcription is an exciting observation.  This 
phenotype has also been observed in overnight cultures grown under non-inducing 
conditions (LB pH 8.5 at 37°C) and in LB at 37°C (Anthouard and DiRita, unpublished 
data).  That ToxR and TcpP can be present without activating toxT transcription led to 
the hypothesis that ToxR and/or TcpP may be post-translationally regulated, and 
toxtazin A is a tool that can be used to induce and study this phenotype.   
Discovering the mechanism of action of toxtazin A and following up on the two 
new hypotheses generated from toxtazin A research will be important future work as it 




Materials and Methods 
Strains used in this study 
The strains used in this study are outlined in Table 3.2, which were maintained at 
-80°C in Luria Bertani broth (LB) containing 20% glycerol.  Cultures were grown 
overnight in LB at 37°C.  Toxin-inducing conditions consist of growing cells in LB pH 6.5 
at 30°C for 16 hours for Classical strain O395 (diluted 1:100), and growing in AKI 
medium as previously described (32) for El Tor strains N16961 and C6706 (diluted 
1:1,000).  Growth in minimal medium consists of diluting an overnight culture 1:100 in 
M9 minimal media supplemented with NERS (M9 salts, 2 mM MgSO4, 4% glycerol, 0.1 
mM CaCl2, and 5 mM each of asparagine, glutamic acid, arginine, and serine) at 37°C 
shaking (33). 
 
Table 3.2.  Strains used in this study. 
Strain or plasmid Relevant genotype or phenotype Source 
 Vibrio cholerae  
O395 Classical Ogawa, SmR Laboratory collection 
N16961 El Tor, SmR Laboratory collection 
C6706 El Tor, SmR Laboratory collection 
Tn::oxyR C6706 Tn::oxyR (26) 
Tn::VC0732 C6706 Tn::VC0732 (26) 
RA2 O395 + ptoxT-gfp (11) 
RA218 O395 + pBAD18-VC0731 This work 
RA247 O395 ΔVC0732 This work 
EK1373 O395ΔtoxRΔtcpP + pSK-ToxR-HA 
 
This work 
EK1372 O395ΔtoxRΔtcpP + pSK 
 
This work 
RA246 SM10λpir + pKAS32-ΔVC0732 This work 
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Deletion of VC0732 
The clean deletion of VC0732 in O395 was generated by mating O395 cells with 
SM10λpir cells containing the pKAS32-ΔVC0732 plasmid.  This plasmid was generated 
by PCR amplifying 500 bp upstream and 500 bp downstream of the VC0732 ORF with 
primers RAP182 (5’-GCAGATGATATCTCAACAGCAGTGTTA-3’) and RAP183 (5’-
GATGGAAGATGTGATTGGTCGTAGTGA-3’), and RAP184 (5’-
TCACTACGACCAATCACATCTTCCATC-3’) and RAP185 (5’-
CTAGCTGAATTCTAAAGTCACTTAAAT-3’), respectively.  The two fragments were 
sown together by overlap extension using primers RAP182 and RAP185, and cloned 
into pKAS32 by restriction digest using EcoRV and EcoRI. 
 
Fractionation 
Wild-type O395 cells were grown overnight under toxin-inducing conditions (LB 
pH 6.5 at 30°C shaking) in the presence or absence of 10 μM toxtazin A, B, or B’.  
Cultures were normalized for OD600, and 5 ml were spun down at 4,000 rpm at 4°C for 
15 minutes.  The pellet was resuspended in 50 μl 0.2M Tris pH 8.0.  To lyse the cells, 
the following were mixed into the sample in succession in this order: 100 μl 0.2M Tris 
pH 8.0 in 1 M sucrose, 10 μl 10 mM EDTA, 10 μl 10 mg/ml lysozyme, 300 μl ddH2O, 
and 10 μl 50x protease inhibitor cocktail.  The samples were incubated on ice for 10 
minutes to allow cell lysis.  Next, 5μl of Roche DNase and 500 μl of 50 mM Tris pH 8.0 
were added to each sample.  The cells were sonicated on ice for a total of 10 seconds 
to further lyse the cells.  The membranes were separated from the cytoplasmic and 
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periplasmic fractions by ultracentrifugation at 65,000 rpm for 60 minutes at 4°C.  The 
pellet was washed once with 500 μl of 50 mM Tris pH 8.0 to minimize contamination 
from the supernatant, and resuspended in 900 μl of 2% TritonX-100/50 mM Tris pH 
8.0/10m M MgCl2 using a 22 gauge needle.  As controls for the efficiency of 
fractionation, expression of EpsL, a known inner membrane protein, was determined by 
Western blot analysis and GFP fluorescence, restricted to the cytoplasm, was 
determined by reading GFP fluorescence in a plate reader (excitation λ = 385 nm, 
emission λ = 425 nm). 
 
DNA gel mobility shift assays 
These were performed as previously described (10).  First, 500 ml cultures of V. 
cholerae strain O395ΔtoxRΔtcpP + pSK-ToxR-HA (strain RA103) and the vector control 
strain O395ΔtoxRΔtcpP + pSK (strain RA104) were grown at 37°C to mid-log, induced 
with 1mM IPTG, and allowed to grow another 4 hrs.  The cells were then pelleted, 
frozen overnight, resuspended in Lysis Buffer (100 mM Tris pH 6.8, 0.75 M sucrose, 2 
mM EDTA, 60 μg/ml lysozyme, and Complete protease inhibitors), and incubated on ice 
for 20 minutes.  The cells were further lysed by two rounds of french pressing at 12,000 
psi.  Unlysed cells and debris were pelleted by centrifugation at 4,000 rpm for 15 min at 
4°C.  The resulting lysate was ultracentrifuged at 35,000 rpm for 90 minutes at 4°C to 
separate the membranes from the cytoplasmic and periplasmic fractions.  The 
membranes were frozen overnight, resuspended in a 5 mM EDTA /25% sucrose 
solution, and quantified using a Pierce BCA protein assay. 
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Next, radiolabeled toxT probe was prepared by PCR amplifying the (-172) to 
(+45) region of the toxT promoter from the pTLI2 plasmid (8) with primers RAP109 (5’-
GTATAGCAAAGCATATTCAG-3’) and RAP 110 (5’-AAATAAACGCAGAGAGC-3’).  The 
PCR product was purified with a MinElute kit and 15 pmol of product was end-labeled 
with T4 polynucleotide kinase (NEB, Ipswich, MA).  The radiolabelled probe was purified 
on an illustra ProbeQuant G-50 column (GE Healthcare, Amersham, UK). 
Twenty microliter binding reactions were prepared in binding buffer consisting of 
10 mM Tris pH 7.4, 1 mM EDTA, 50 μg/ml BSA, 5 mM NaCl, 50 mM KCl, 5% glycerol, 
with 100 μg/ml salmon sperm DNA, 3 μl of radiolabeled toxT probe (at 3,000 cpm/μl), 
and varying amounts of membrane preps.  Compound was added at either 10 or 50 μM, 
and DMSO was added at an equivalent volume.  Binding reactions were incubated at 
30°C for 30 minutes before being run on a 6% polyacrylamide gel, which had been pre-
run for 20 minutes with 5% thioglycolate.  The gel was run for 720 Vhrs, dried on a 
vacuum dryer, and exposed to a piece of film or to a phosphor screen. 
 
Comparative proteomics 
Cells were grown overnight under toxin-inducing conditions (LB pH 6.5 at 30°C) 
in the presence or absence of 10 μM toxtazin A.  Cells were pelleted, washed twice in 
PBS, and proteins were separated by SDS-PAGE.  Proteins were in-gel digested then 
identified by liquid chromatography and tandem mass spectrometry (gel LC-MS/MS) at 
MS Bioworks in Ann Arbor, MI.   
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Detection of cholera toxin by ELISA 
Cultures of V. cholerae were grown under toxin-inducing conditions for 16-18 
hours with 10 μM compound or DMSO. GM1 ganglioside enzyme-linked immunosorbent 
CT assays were performed as previously described (34) on equal volumes of the 
resulting supernatants. CT expression values were normalized to OD600 and are the 
average of samples grown in triplicate.  
 
Transposon mutagenesis 
Overnight cultures of the parent strain O395 + ptoxT-GFP (RA2) and the donor 
strain SM10λpir + pFD1 (RA150b) were grown in 100 μg/ml streptomycin and 100 μg/ml 
ampicillin, and 100 μg/ml ampicillin and 50 μg/ml kanamycin, respectively. Seven-
hundred and fifty milliliters of each culture was spun down for five minutes at 12,000 
rpm to pellet the cells, the cells were washed once in PBS, and both strains were 
combined in 50 μl LB.  This mixture was spotted onto a thick LB agar plate and allowed 
to grow at 37°C for three hours, after which time they were resuspended in 10 ml LB + 1 
mM IPTG and grown in a 50 ml flask at 37°C.  After three hours of growth, the culture 
was plated on agar plates containing ampicillin, kanamycin, and streptomycin to select 
for V. cholerae with the transposon.  The resulting colonies were pooled to generate the 




Mutants pools generated by transposon insertion of by continual growth for 30 
days (labeled sp for spontaneous) were grown for 16 hours in LB pH 6.5 at 30°C with 
either 50 μM toxtazin A (note: This batch of toxtazin A was not toxic to cells at 50 μM), 
10 μM toxtazin B, or an equivalent volume of DMSO.  These cultures were then diluted 
1:16 to be amenable to sorting, and run through the flow cytometer.  The cells within the 
2-5% highest GFP signal were sorted and plated on LB agar plate supplemented with 
streptomycin, ampicillin, and kanamycin.  Colonies were transferred to a single well of a 
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Mechanism of Action of Toxtazin B 
 
Summary 
Similarly to toxtazin A, both a loss-of-target approach and two unbiased 
screening approaches were employed to determine the mechanism of action by which 
toxtazin B inhibits pathogenesis in Vibrio cholerae.  Preliminary evidence suggests that 
toxtazin B may exert its effects on virulence gene regulation through AphB.  While the 
exact mechanism of action has not yet been identified, many potential mechanisms 
have been ruled out.  The results of this research are presented here, and implicate 
proteins involved in regulating the tcpP promoter. 
 
Introduction 
Vibrio cholerae produces and secretes cholera toxin (CT) into the lumen of its 
host, resulting in cramping and diarrhea (1).  Production of CT is tightly regulated by the 
virulence cascade, which has multiple layers of regulation.  Transcription of the ctxAB 
operon, which encodes CT, is activated by ToxT (2), which is activated by ToxRS and 
TcpPH, two inner membrane transcriptional activators and their respective effector 
proteins (3-7). Previously, two small molecule inhibitors of toxT transcription, toxtazin A 
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and toxtazin B, were identified, and toxtazin B was found to inhibit tcpP transcription but 
not AphA or AphB protein levels (8). 
TcpP expression is activated by the transcriptional activator AphA (9), which is 
involved in quorum sensing (10), and AphB (11), which increases tcpP transcription in 
response to low pH (12) and to anaerobiosis growth conditions via a thiol switch at 
residue C227 (13). 
The tcpP promoter assimilates multiple additional signals including the cAMP-
CRP complex (14) and phosphate levels (15).  In addition, in the absence of TcpH or 
upon sensing non-inducing conditions, pre-existing TcpP in the cell is removed by 
sequential degradation by the Tsp (Teoh, W.P. and DiRita, V.J., unpublished) and YaeL 
proteases (16). This complex system ensures TcpP is present in the cell only under the 
right conditions.   
Through careful investigation of the multiple layers of TcpP regulation, we 
present evidence that toxtazin B does not promote Tsp/YaeL-mediated degradation of 
TcpP, nor does it prevent AphA or AphB from binding the tcpP promoter in vitro.  
Toxtazin B may inhibit tcpP transcription by mimicking an anaerobic state, by 
potentiating cAMP-CRP binding to the tcpP promoter, or potentiating PhoB inhibition at 




Toxtazin B reduces Vibrio cholerae colonization of infant mice in a ToxT-dependent 
manner  
We demonstrated that toxtazin B reduces colonization loads of V. cholerae in an 
infant mouse model in Chapter 2 (8).  To rule out the possibility that toxtazin B acts as 
an antibiotic and kills V. cholerae, V. cholerae, strain S533 was tested.  This strain 
colonizes the infant mouse through a mechanism that does not require toxT, tcp, or 
ctxAB, none of which is encoded in its genome, (17).  The S533 strain was tested in 
infant mice following the same protocol used for the O395 strain in Chapter 2.  Either 
100 μg toxtazin B or an equal volume of DMSO were gavaged into mice along with 106 
C.F.U. of S533, followed by a boost of either 100 μg toxtazin B or an equal volume of 
DMSO three hours later.  After the boost, the infection was allowed to proceed for 16 
hours, after which time mice were euthanized and the intestines removed.  The number 
of S533 bacteria present in the intestine was enumerated by plating 10-fold dilutions on 
selective media.  Unlike colonization by the classical strain V. cholerae O395 (Chapter 
2), there was no significant difference in the colonization loads of strain S533 in mice 
treated or un-treated with toxtazin B (Figure 4.1).  From this we conclude that toxtazin B 
targets the ToxR/TcpP/ToxT regulatory system both in vivo and in vitro.   
 
Toxtazin B does not stimulate TcpP degradation 
Toxtazin B has been shown to reduce tcpP transcript as well as TcpP levels 






A.      B. 
  
Figure 4.1 Colonization of S533 is not affected by toxtazin B.   
A. Number of V. cholerae recovered from mice orogastrically inoculated with 106 
of the S533 strain of V. cholerae treated with either DMSO or 200 μg toxtazin B.  
Number of S533 V. cholerae recovered from three mL cultures grown overnight with the 
same inocula and boosts as the mice in 4.1A. p-values were determined by a non-
paired 2-tailed t-test.   
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the presence or absence of toxtazin B under toxin-inducing conditions (LB pH 6.5 at 
30°C), and TcpP levels were measured every hour by running lysates on a 12.5% SDS-
PAGE gel.  Supernatants from each time point were analyzed for CT by ELISA.  Where 
TcpP levels in DMSO-treated cultures stayed relatively steady during the 24-hour 
growth period, TcpP levels in toxtazin B-treated cells decreased over time (Figure 4.2A), 
consistent with our results in Chapter 2.  
One curious result from this experiment is that, despite the fact that TcpP was 
present in cultures at early time points, CT production was not observed.  We 
hypothesize a post-translational level of TcpP regulation in the virulence cascade that 
turns TcpP from an OFF to an ON state; however more work needs to be done to 
confirm this and uncover the nature of this regulation. 
Previous work demonstrated that toxtazin B reduces tcpP transcript levels by 
50% in cells (Chapter 2; (8)); is reasonable to hypothesize that TcpP levels decrease 
because of a reduction in tcpP transcription.  However, it is also known that under 
conditions unfavorable for toxin expression, TcpP is degraded in a two-step proteolytic 
pathway, with Tsp acting first, and YaeL acting on the Tsp-cleaved TcpP* product 
(unpublished data and (16)).  Therefore, toxtazin B may decrease TcpP steady-state 
levels by both inhibiting tcpP transcription and stimulating TcpP proteolysis.  It is also 
possible that TcpP proteolysis could result in tcpP transcription inhibition by a feedback 
mechanism.   
To rule in or out the possibility that toxtazin B may stimulate TcpP degradation in 
addition to inhibiting tcpP transcription, we used two different approaches.  First, we 
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Figure 4.2 Toxtazin B does not stimulate TcpP degradation. 
A. TcpP levels over time in cultures treated with DMSO or 10 μM toxtazin B.  CT 
levels, determined by CT ELISA, are shown below each sample.  B. TcpP steady-state 
levels in cultures grown overnight under toxin-inducing conditions with DMSO or 10 μM 
toxtazin B added at various times.  EpsL was used as a loading control. CT levels, 
determined by ELISA, are indicated below each sample.  C. TcpP Western blot of a 
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 added toxtazin B to cultures at varying stages of growth and monitored TcpP levels 
after 16 hours of exposure to toxtazin B.  We reasoned that if toxtazin B induces TcpP 
degradation, TcpP levels that accumulate prior to addition of toxtazin B will decrease 
after its addition.  Parallel cultures of wild-type cells were grown overnight in LB and 
diluted 1:100 in LB pH 6.5, followed by growth at 30°C to induce toxin expression.  
DMSO or toxtazin B was added to two tubes every hour, and the OD600 was noted.  
Cultures were then grown for 16 hours after toxtazin B addition such that all cells were 
exposed to toxtazin B for the same amount of time.  After 16 hours of growth, cell pellets 
were analyzed for TcpP levels and supernatants were analyzed for CT expression 
(Figure 4.2B).  Western blot analysis for TcpP shows that toxtazin B has a stronger 
effect on TcpP levels the earlier it is added to the culture.  When toxtazin B was added 
to cultures after one hour of growth, TcpP levels are severely decreased after 16 hours.  
However, if the culture was allowed to grow for eight hours before toxtazin B was added, 
TcpP levels did not decrease, despite having been exposed to toxtazin B for the same 
amount of time.  These results lead to the conclusion that toxtazin B affects the steady-
state levels of TcpP protein in the cell by reducing the input of TcpP, not by increasing 
its turn-over.   
Secondly, we tested whether toxtazin B induces Tsp-dependent cleavage of 
TcpP under toxin-inducing conditions.  In a strain lacking YaeL grown under non-
inducing conditions, TcpP is degraded by Tsp to yield a TcpP* fragment, but because 
YaeL is not present to degrade it further, the TcpP* fragment accumulates and can be 
detected by Western blot (16).  We reasoned that if toxtazin B works by doubly inhibiting 
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tcpP transcription and by stimulating TcpP degradation, the TcpP present early in the 
culture (see Figure 4.2A) would be cleaved by Tsp, resulting in the accumulation of 
TcpP*.  After 16 hours of growth under toxin-inducing conditions, TcpP is partially 
degraded by Tsp, as seen by the TcpP* band in DMSO-treated cells as well as in 
toxtazin A-treated cells (Figure 4.2C).  In contrast, no TcpP or TcpP* is seen in cells 
treated with toxtazins B or B’.  The lack of TcpP* accumulation suggests that TcpP is 
not degraded by the Tsp/YaeL pathway in the presence of toxtazin B.  Taken together, 
our results indicate that toxtazin B inhibits tcpP transcription but not TcpP proteolysis by 
Tsp/YaeL. 
 
Toxtazin B does not inhibit AphA or AphB from binding the tcpP promoter 
Having eliminated the possibility that toxtazin B may promote the degradation of 
TcpP, we focused on the mechanism by which toxtazin B inhibits tcpP transcription 
(chapter 2, Figure 4).  One possible mechanism is that toxtazin B may inhibit AphA or 
AphB from binding the tcpP promoter.  To test this, AphA and AphB were purified and 
electrophoretic mobility shift experiments were performed with a radiolabeled tcpP 
probe as described previously (14).  Either 10 μM or 50 μM toxtazin B or an equivalent 
volume of DMSO was added to the binding reactions, incubated for 30 minutes at 30°C, 
and the reactions were subjected to electrophoresis on a 6% polyacrylamide gel.  
Toxtazin B did not affect the ability of either AphA or AphB to bind the tcpP promoter, 
even at the higher concentration (50 μM) than typically used with this compound. 
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Figure 4.3 Toxtazin B does not inhibit AphA or AphB binding to the tcpP promoter 
AphA (panel A) and AphB (panel B) were purified and incubated with 
radiolabeled tcpP probe in the presence or absence of 10 μM or 50 μM toxtazin B, then 
run on a 6% polyacrylamide gel.  An excess of cold tcpP probe was added in the last 
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The AphB thiol switch mutant C227S may be resistant to toxtazin B  
Published evidence suggests that AphB induces tcpP transcription upon sensing 
anaerobic conditions via a thiol switch at residue C227, and that a C227S mutant is 
constitutively active (13).  We hypothesized that toxtazin B may interfere with the thiol 
switch in AphB.  
When ΔaphB cells complemented with an arabinose-inducible plasmid containing 
a wild-type AphB allele were grown overnight under toxin-inducing conditions (LB pH 
6.5 at 30°C), CT expression was induced in an arabinose-dependent manner (Figure 
4.4).  Upon treating these cells with 10 μM toxtazin B, CT levels were reduced, as 
expected.  However, if the experiment was repeated with ΔaphB cells complemented by 
an arabinose-inducible plasmid containing the C227S allele of aphB, CT production was 
resistant to toxtazin B treatment (Figure 4.4).  While these results are preliminary, they 
suggest that the AphB – more specifically the putative thiol switch within AphB – may be 
a toxtazin B target.  This experiment requires reconstitution of a chromosomally-
encoded aphBC227S allele to determine whether this thiol switch is important for 
toxtazin B activity, to rule out a more trivial effect of protein expression levels. 
 
 A transposon mutagenesis screen for toxtazin B-resistant mutants 
Just as for toxtazin A, attempting to identify a transposon or spontaneous mutant 
resistant to toxtazin B by FACS sorting was unsuccessful.  See chapter 3 for a full 







Figure 4.4. CT expression of cells expressing the wild-type or C227S allele of AphB 
Cultures of ΔaphB cells complemented with arabinose-inducible wild-type or C227S 
alleles of AphB were grown overnight under toxin-inducing conditions in the presence or 
absence of arabinose and in the presence or absence of 10 μM toxtazin B.  The 
resulting supernatants were analyzed to determine the amount of CT secreted.  Error 
































While the precise mechanism of action of toxtazin B is still unclear, here we 
tested several hypotheses and ruled some of them out, while generating new ones 
based on these findings.  One specific point that was clarified in this work is that mouse 
colonization loads of V. cholerae in mice treated with toxtazin B are reduced likely as a 
result of the effect of toxtazin B on toxT expression, as opposed to a general anti-
bacterial effect in vivo.  We conclude this based on our observation that the S533 strain 
of V. cholerae, which colonizes through a mechanism that does not depend on ToxT, 
was unaffected for colonization when mice were treated with toxtazin B.  This is in 
contrast to the effect of toxtazin B on colonization of the classic V. cholerae strain 0395 
(Chapter 2).   
Our original observation regarding toxtazin B was that cells exposed to this 
compound have reduced expression of toxT and that was associated with a similar 
decrease in TcpP protein and transcript levels in overnight cultures (Chapter 2; (8)).  We 
speculated that, in addition to reducing tcpP gene expression, toxtazin B might also 
cause degradation of TcpP protein, which is understood to occur under particular growth 
conditions (16, 18).  Here we explored this possibility further.  Cells grown under toxin-
inducing conditions without toxtazin B in the medium accumulated TcpP that remained 
stable after addition of the compound.  However if toxtazin B were present at the start of 
the culture, TcpP did not accumulate, suggesting that it is not expressed in the presence 
of the compound.  AphA and AphB, the transcriptional activators of the tcpP promoter, 
were still capable of binding the tcpP promoter at least in vitro, ruling out direct alteration 
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of their function by the compound.  It remains possible that toxtazin B could disrupt the 
ability to bind DNA inside the cell, which could be examined further with an in vivo DNA 
binding assay such as chromatin immunoprecipitation.   
A post-translational level of regulation may exist for either AphA or AphB, as has 
been suggested by another group studying AphB (13).  In this model, AphB activity is 
regulated by the redox status of the cell, sensed by the reduction or oxidation of a key 
cysteine residue, C227.  This redox sensor may be important in toxtazin B activity, as 
toxtazin B does not reduce CT expression in cells expressing AphB-C227S, though 
further analysis needs to be done to confirm this.  Discovering the mechanism of action 
of toxtazin B is important, as it will likely provide new insight into the regulation of the 
tcpP promoter, an important step in virulence gene regulation in V. cholerae. 
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Materials and Methods 
Infant mouse colonization assays 
Four to six day-old CD1 mice (Charles River, Wilmington, MA) were 
orogastrically inoculated with a 30 μl bolus containing 106 CFU of V. cholerae S533, 
Cremaphor EL (20% final volume to solubilize compounds), and either DMSO or 200 μg 
toxtazin B. An additional 30 μl bolus lacking bacteria was delivered to each mouse three 
hours post-inoculation, and the mice were incubated at 30°C. Mice were euthanized 18-
24 hours after inoculation, the intestines were isolated, weighed, and homogenized in 
PBS.  Homogenates were serially diluted and plated on LB agar + X-gal + streptomycin 
to determine the number of CFU recovered.  CFUs were normalized to the weight of the 
intestines and to the exact CFU of the initial inoculum.  Significance was determined 
using one-way ANOVA.  Three milliliter of LB was inoculated and treated as the mice 
were, to control for toxtazin toxicity. 
 
Western blot analysis of TcpA, ToxR, TcpP, AphB, and AphA 
Cells were cultured under toxin-inducing conditions in the presence or absence of 
10 μM toxtazin B, and c. ell extracts were subjected to SDS-PAGE, transferred to a 
nitrocellulose membrane (GE Water and Processes Technologies, Feasterville-Trevose, 
USA), probed with TcpP antiserum (diluted 1:500), and visualized by alkaline 
phosphatase.  EpsL antibodies were used as a loading control, diluted 1:10,000. 
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DNA gel mobility shift assays 
These were performed as previously described (11).  AphA and AphB were 
purified from BL21 cells expressing pET32-AphA-His (strain RA304) or expressing 
pET32-AphB-His (strain RA313).  One-hundred milliliters of culture was grown for two 
hours at 37°C shaking, then shifted to 16°C for one hour.  Expression was induced with 
one mM IPTG, and the culture was allowed to grow for another 12-16 hours at 16°C.  
The cells from these cultures were pelleted and frozen at -80°C for 20 min or longer.  
Cells were lysed with eight ml Native Binding Buffer (50 mM NaH2PO4 pH 8.0, 2.5 M 
NaCl), one μl Benzonase and one Complete Mini Protease inhibitor tablet were added.  
Eight mg lysozyme was added and allowed to lyse the cells by incubating for 30 min on 
ice.  Cells were then sonicated on ice for a total of 60 sec.  The lysates were spun for 15 
min at 3,000g at 4°C to pellet unlysed cells and debris.  The clear lysate was applied to 
a 10 ml nickel column with 1.5 ml of resin, which had been pre-washed with ddH2O and 
Native Binding Buffer.  The His-tagged proteins were allowed to bind the nickel resin by 
rocking in the column for one hour at 4°C, and the resin was allowed to settle by gravity 
before letting the lysate flow through.  Native Wash Buffer (50 mM NaH2PO4 pH 8.0, 2.5 
M NaCl, 20 mM imidazole) was used to wash the column 3 times before eluting the 
purified His-tagged protein from the column with Native Elution Buffer (50 mM NaH2PO4 
pH 8.0, 2.5 M NaCl, 250 mM imidazole).  The resulting fractions 2 and 3 were dialyzed 
into 1X Native Purification Buffer overnight, then diluted 1:1 in glycerol and stored at -
80°C until needed. 
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Next, radiolabeled tcpP probe was prepared by end-labeling 40 ng of the forward 
primer RAP222 (5’-GATCCGAATTCCTGTAACGAATATTGCTTCCG-3’) with 4 μl of γ-
32P (10 mCi/ml) using T4 polynucleotide kinase (NEB, Ipswich, MA).  This primer was 
ethanol precipitated and used to PCR amplify the tcpP promoter from a plasmid-derived 
sequence (in strain RA330) with the reverse primer RAP223 (5’-
GATCGGGATCCTTTCTTAATCATAACGACCC-3’).  The PCR product was ethanol 
precipitated and resuspended in 25 μl ddH2O.   
Thirty microliter binding reactions were prepared in binding buffer consisting of 10 
mM Tris*OAc pH 7.4, 1 mM K*EDTA pH 7.0, 100 mM KCl, 1 mM DTT, 10% glycerol, 
0.3 mg/ml BSA, and 100 μg/ml salmon sperm DNA mixed with 3 μl radio-labeled tcpP 
promoter probe, 10 μM or 50 μM toxtazin B, and varying concentrations of purified 
AphA or AphB.  Binding reactions were incubated for 30 min at 30°C, then run on a 6% 
polyacrylamide gel for 600 Vhrs.  The gels were dried on a vacuum dryer and exposed 
to film.  Electromobility shift assays were repeated on three separate days. 
 
Detection of cholera toxin by ELISA 
Cultures of V. cholerae O395ΔaphB + pBAD-aphBwt or O395ΔaphB + pBAD-
aphBC227S (kindly provided by Dr. Jun Zhu) were grown under toxin-inducing conditions 
for 16-18 hours with 10 μM compound or DMSO. GM1 ganglioside enzyme-linked 
immunosorbent CT assays were performed as previously described (19) on equal 
volumes of the resulting supernatants. CT expression values were normalized to OD600 
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This dissertation describes the identification of small molecules that inhibit the 
virulence cascade in Vibrio cholerae.  We detail the in vitro and in vivo activities of two 
identified compounds, toxtazin A and toxtazin B, and present evidence that toxtazin A 
targets toxT transcription while toxtazin B targets tcpP transcription.  Here, we 
summarize our findings, discuss possible mechanisms of action for toxtazins A and B, 
and consider the potential of each compound as molecular probes for scientific 
discovery and as therapeutic leads for the treatment of cholera.  We conclude with a 
discussion on the impact of this work in the greater context of bacterial pathogenesis 
and drug discovery. 
 
Toxtazins A and B inhibit virulence gene expression in Vibrio cholerae 
Using a toxT-GFP reporter strain of V. cholerae, 63,000 small molecules were 
screened for those that reduce toxT transcription in live cells, leading to the discovery of 
toxtazins A and B.  The reduction in GFP expression was due to a decrease in toxT 
transcription and not an effect on the GFP reporter because cholera toxin (CT) levels in 
cells were also reduced in cell treated with either toxtazin A or B.  Additionally, toxtazin 
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A- or B-treated cells express less TcpA, the toxin co-regulated pilus, which is 
transcriptionally activated by ToxT. 
In addition to their activity in vitro, these compounds were tested in an infant 
mouse model of colonization to assess their in vivo activity.  While toxtazin A was toxic 
to bacteria at just 60 μg/ml and therefore not testable in this model, toxtazin B was not 
toxic to bacteria even at 200 μg/ml.  Treating mice with 200 μg of toxtazin B significantly 
reduced colonization of the classical O395 strain of V. cholerae.  However, the S533 
strain of V. cholerae, which colonizes mice through a ToxT-independent mechanism, 
was not affected by the same dose of toxtazin B, indicating that toxtazin B reduces 
colonization in a ToxT-dependent manner.  
 
Toxtazin A targets toxT transcription while toxtazin B targets tcpP transcription 
Toxtazin A does not affect ToxR protein levels, ToxR activity at the ompU or 
ompT promoters, ToxR localization to the membrane, or the ability of ToxR to bind the 
toxT promoter.  Furthermore, toxtazin A does not affect TcpP protein levels or its 
localization to the membrane.  TcpP binding to the toxT promoter in the presence of 
toxtazin A is currently being evaluated.  Taken together, our results indicate that toxtazin 
A targets toxT transcription. 
Toxtazin B also does not affect ToxR protein levels, its activity at the ompU or 
ompT promoters, or it localization to the membrane.  However, it reduces TcpP protein 
levels as well as tcpP transcript levels.  Toxtazin B does not induce Tsp/YaeL-mediated 
proteolysis of TcpP, ruling out the possibility that toxtazin B causes the cells to respond 
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as though they are growing under non-inducing conditions.  AphA and AphB, the 
transcriptional activators of tcpPH, are not inhibited by toxtazin B.  Both are expressed 
at normal levels and both are able to bind the tcpPH promoter, suggesting that toxtazin 
B inhibits tcpP transcription independently of AphA or AphB. 
  
Toxtazin A affects the envelope, nutrient, and redox stress responses 
Toxtazin A-treated cells are unable to respond to envelope or nutrient stress, and 
seem to be responding to redox stress.  V. cholerae responds to envelope stress, 
induced 3% ethanol, by activating an alternative sigma factor, σE, encoded by rpoE (1).  
In the presence of toxtazin A, cells cannot grow in 3% ethanol, suggesting they are 
unable to cope with envelope stress.  It is possible that rpoE is important for virulence 
gene activation because an rpoE mutant is deficient for colonization of infant mice (1). 
Therefore, it is possible that toxtazin A inhibits RpoE activation, and that this could 
inhibit the virulence cascade.  This hypothesis is currently under investigation.  
Similarly, cells grown in M9 minimal media + 0.4% glycerol + NERS cannot grow 
in the presence of toxtazin A.  Because cells treated with toxtazin B grow normally 
under these conditions, it is unlikely that the growth defect is due to inhibition of the 
virulence cascade, but is rather likely due to nutritional stress.  Typically, nutritional 
stress in bacteria leads to changes in gene expression known as the stringent response, 
which is triggered in large part by the intracellular accumulation of guanosine 3’-
diphosphate 5’-triphosphate and guanosine 3’,5’-bis(diphosphate), collectively called 
(p)ppGpp (2).  V. cholerae experiencing fatty acid or glucose starvation activate SpoT 
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and RelV proteins to synthesize (p)ppGpp, and cells under amino acid starvation 
activate RelA, which also activates and synthesizes (p)ppGpp.  Together with DskA, 
(p)ppGpp responds to nutrient stress by activating motility, biofilm formation, and CT 
expression (3).  A relA mutant has a severe growth defect in minimal media (4, 5), 
suggesting that a (p)ppGpp is required for virulence.  Given that the stress response is 
important for virulence in vivo, it is possible that toxtazin A may inhibit the stringent 
response or prevent (p)ppGpp synthesis, which could in turn inhibit toxT transcription.  
This hypothesis is currently being tested. 
Additionally, cells treated with toxtazin A behave as though they are responding 
to redox stress.  Proteomic analysis revealed that cells treated with toxtazin A increase 
the expression of 20 proteins, seven (35%) of which are involved in redox homeostasis. 
The oxidative stress response in V. cholerae is not well characterized, but it is known to 
be mediated through OxyR (6) and that quorum sensing can activate production of 
RpoS, which responds to both oxidative stress (6, 7) and carbon starvation (8).  While 
OxyR and RpoS are dispensable for colonization of infant mice (6, 8), this may be 
simply because OxyR and RpoS are not induced in this in vivo model. It remains 
possible that toxtazin A may induce an oxidative stress response, and that part of that 
response results in shutting off toxT transcription.   
 
Toxtazin B may affect AphA or AphB activity post-translationally 
We showed in chapter 2 that toxtazin B inhibits virulence by targeting tcpP 
transcription.  The mechanism by which this is accomplished is still being experimentally 
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determined; however, a few key possibilities have been ruled out.  First, the possibility 
that toxtazin B induces Tsp/YaeL-mediated cleavage of TcpP was ruled out.  If toxtazin 
B promoted Tsp/YaeL-regulated proteolysis, a TcpP* band should accumulate in a 
ΔyaeL mutant treated with toxtazin B, but this was not observed.  In addition, toxtazin B 
does not decrease TcpP expression when added to cells already expressing TcpP. 
The possibility that AphA or AphB cannot bind the tcpP promoter in the presence 
of toxtazin B has also been ruled out.  Gel shift experiments with purified AphA or AphB 
showed that toxtazin B does not affect the ability of either of these proteins to bind to the 
tcpP promoter, at least in vitro.  Toxtazin B may affect post-translational regulation of 
either AphA or AphB, which could affect binding to the tcpP promoter in vivo.  
Supporting this hypothesis is the fact that cysteine 227 of AphB is post-translationally 
modified, and that this modification is important for its activity at the tcpP promoter (9).  
Distinct modifications to cysteine residues in proteins have been proposed to result in 
various protein activation states, leading to different phenotypic outcomes depending on 
the type of modification (10).  It is possible that toxtazin B could inhibit AphB activity by 
affecting the modification at the C227 residue, a hypothesis supported by the finding 
that cells expressing AphBC227S are resistant to toxtazin B (Figure 4.4).  While AphA has 
not been shown to undergo post-translational modifications, it does contain two cysteine 
residues and thus has the potential to also be modified.  
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Small molecule screens as hypothesis-generating research 
One key advantage of small molecule screening approaches is the testable 
hypotheses generated by this type of research.  In the case of toxtazin A, my evidence 
suggests that ToxR and TcpP can be present in the inner membrane and yet do not 
activate toxT.  Toxtazin A treatment is not the only condition that results in ToxR and 
TcpP being present in the membrane without activating toxT transcription- it is also seen 
in stationary cells grown in toxin non-inducing conditions (growth in LB pH 8.5 at 37°C) 
or grow at 37°C in LB (unpublished results, Anthouard and DiRita).  Growth on malonate 
also inhibits toxT transcription as well as tcpA and ctxAB transcription, though ToxR and 
TcpP are not affected (11).  These results suggest that ToxR and TcpP are necessary 
but not sufficient for toxT activation, and perhaps another protein or post-translational 
modifications to either ToxR and/or TcpP is required for activation of toxT.  Toxtazin A 
will be a useful tool in testing this hypothesis. 
Follow-up studies with toxtazin A also generated the hypothesis that cellular 
stress could feedback to the virulence cascade and shut it off by stopping transcription 
of toxT.  Many pathogenic bacteria shut off virulence gene expression in response to 
stress, including Staphylococcus aureus (12), Listeria monocytogenes (13, 14), Brucella 
melitensis (15), Pseudomonas aeruginosa (16), and Klebsiella pneumoniae (17).  While 
this has not been directly tested in V. cholerae, many genes involved in stress response 
are required for colonization in vivo, including those that respond to nitrosative stress 
(18, 19), nutrient stress (4), and extracytoplasmic stress (1).  In addition, a recent study 
found that ethanol-induced extracytoplasmic stress, signaled by σE, resulted in the 
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transcriptional down-regulation of toxT and ctxAB but did not affect tcpP or toxR 
transcription (20).  These findings suggest that stress responses may indeed regulate 
the virulence cascade in V. cholerae, but further work is needed to determine if this is 
the mechanism by which toxtazin A decreases toxT transcription. 
 
Toxtazin B as a potential therapeutic lead 
Small molecule screens often result in the identification of compounds that could 
theoretically have medicinal use in treating disease.  For example, we have shown that 
toxtazin B reduces colonization of infant mice by 2 logs, indicating that it functions in 
vivo and thus could have potential therapeutic use.  While the pharmacological 
characterization and drug development of toxtazin B still remains to be done, this 
molecule is attractive as a therapeutic lead because it affects toxin-expressing V. 
cholerae only.  A strain of V. cholerae lacking the virulence genes toxT, tcpA, and ctxAB 
colonized mice equally whether the mice received toxtaxin B or DMSO carrier.  This kind 
of specificity in vivo suggests that the compound would do minimal damage to other 
bacteria, theoretically leaving the microbiota unaffected by toxtazin B treatment.    
 
Future Perspectives 
While the mechanism of action for toxtazins A and B are still being worked out, 
new knowledge about the virulence cascade has already been generated from studying 
these molecules.  For example, toxtazin A will serve as a tool to study the putative post-
translational modifications to either ToxRS and/or TcpPH that are required for toxT 
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activation, mechanisms that have been previously proposed by others (21-23).  
Additionally, work with toxtazin A has led to the hypothesis that stress responses in V. 
cholerae may inhibit expression of toxT.  Following up on these hypotheses in the future 
will further our understanding of how the virulence cascade in V. cholerae is regulated.  
It would also prove potentially insightful to perform an RNAseq experiment on cells 
treated with or without toxtazin A, to gain an understanding of what role(s) various 
stress signals play in regulating the virulence cascade. 
In the case of toxtazin B, which targets transcriptional activation of the tcpP 
promoter, we have learned from our in vivo experiments that targeting tcpP transcription 
is a valid approach to designing new therapeutics for treating V. cholerae colonization.  
Performing some SAR, pharmacokinetic and pharmacodynamics studies would be the 
next step to developing this compound for potential clinical use.  Additionally, follow-up 
work on the MOA of toxtazin B would also provide a deeper understand of how the 
virulence cascade in V. cholerae is regulated.  Experiments looking at AphA and AphB 
post-translational modifications, in particular their disulfide-bonded state, are already 
underway and may corroborate with early findings about redox sensing by these 
proteins (9). 
The work presented here serves as an example of the power of chemical 
genetics in both uncovering new biologically relevant information and in uncovering the 
“druggable” aspects of a pathogen’s virulence machinery for the development of 
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While the toxtazins identified in the synthetic small molecule screen have 
provided insight into the cellular requirements for virulence gene regulation by Vibrio 
cholerae, they are not compounds naturally found in nature.  Natural products were also 
screened for those that inhibit Vibrio cholerae pathogenesis using the toxT-gfp reporter 
strain NB39 used in Chapter 2.  Two libraries were screened- a natural extract library 
from the Center for Chemical Genomics (CCG) at the University of Michigan, and a 
portion of the Biolog plates.  Twenty-nine natural compounds inhibited toxT transcription, 
including procaine, lidocaine, and maltose, which were chosen for follow up studies 
presented here. 
   
Introduction 
There is an added benefit to screening naturally occurring molecules in that these 
may be biologically relevant molecules that V. cholerae may sense and respond to in its 
normal lifecycle.  For example, V. cholerae senses cyclic di-guanosine monophosphate 
(c-di-GMP) through VpsT and VpsR and responds by inducing biofilm formation (1, 2).  
V. cholerae is also capable of sensing chitin and responding by becoming naturally 
competent (3).  Thus, natural products could uncover ways in which a bacterium’s 
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environment regulates gene expression.  In addition, natural products tend to be larger, 
less molecularly flexible, more chemically diverse, have different polarity, aromaticity 
content, heteroatom content, and occupy different areas of chemical space (4, 5), 
making potential natural product hits different from the hits identified in synthetic small 
molecule screens.  To broaden our search for inhibitors of toxT gene expression in V. 




The CCG collaborates with Dr. David Sherman to obtain natural product extracts 
from various marine ecosystems throughout the world including Papua New Guinea, 
Costa Rica, US Virgin Islands, Panama, Lake Erie, Lake Huron and Antarctica.  We 
screened 11,121 extracts using our toxT-gfp reporter strain and identified 456 that 
reduced toxT-GFP expression by 6 standard deviations of the mean without affecting 
growth by more than 10%, a 4.1% hit rate.  
The best natural product extract was chosen for follow up and the strain stock 
was cultured to reproduce the extract in a 3 L and 6 L culture size.  Unfortunately, 
neither of these culturing methods produced extracts capable of reducing toxT-GFP 
activity.  This illustrates some of the major issues in working with natural products- the 
results are not always reproducible, and recreating the same extract is often difficult (6).  
Because of these caveats, we prioritized the toxtazins for further analysis, as opposed 
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to the natural products.  However, this and the other hits generated from screening the 
natural products library at the CCG could be of interest in future studies. 
 
Biolog Screen 
Biolog phenotypic microarrays have been successfully used in pathogenesis 
research to identify natural molecules that inhibit bacterial growth on beef (7), to identify 
substrates that persister cells use for respiration (8), and to further drug discovery by 
grouping compounds with similar mechanisms of action (9).  To determine if any of the 
natural compounds in the Biolog phenotypic microarray could inhibit toxT transcription, 
the compounds in each Biolog plate was resuspended in toxin-inducing medium (LB pH 
6.5), and each well was inoculated with a 1:100 dilution of an overnight culture of the V. 
cholerae toxT-GFP reporter strain and incubated at 30°C for 16-18 hours without 
shaking.  GFP and OD600 levels were read to determine the level of growth and toxT 
activation in the presence of each compound, and the % inhibition was calculated as 
follows: (FL/OD600)treated/(FL/OD600)untreated *100.  Twenty-seven compounds were 
identified that significantly reduce toxT-GFP expression by 30% or more relative to 
untreated samples (see Table A1.) 
In addition to the typical toxin-inducing conditions (LB pH 6.5 at 30°C), the 




Table A1 Natural compound inhibitors of toxT-GFP in LB pH 6.5 at 30°C. 
Compound % Inhibition 
Iodonitro Tetrazolium violet 92.03 
Chorpromazine 51.86 





Sodium bromate 40.31 
Arg-Arg dipeptide 40 
D-Tagatose 39.49 
Procaine 39.07 
γ-Amino butyric acid 38.54 
Sodium azide 38.15 
1,10-Phenanthroline 37.16 
Sodium pyrophosphate decahydrate 35.77 
Meadione 35.76 




Quinic acid 32.22 
Sodium dichromate 31.7 
Azathioprine 31.34 
Arg-Lys dipeptide 31.15 
Xylitol 30.88 
Ala-Tyr dipeptide 30.18 




condition- M9 minimal media with glycerol as the carbon source, supplemented with 
asparagine, glutamate, arginine, and serine (NERS) grown at 30°C.  After resuspending 
the compounds in this medium, each well was inoculated with a 1:100 dilution of an 
overnight culture of the V. cholerae toxT-GFP reporter strain, and the cultures were 
grown at 30°C for 16-18 hours without shaking.  The GFP and OD600 levels were read to 
determine the level of growth and GFP expression in the presence of each compound, 
and the % inhibition was calculated as follows: (FL/OD600)treated/(FL/OD600)untreated *100.  
Twelve compounds that inhibit toxT-GFP expression by 30% or more were identified 
(Table A2). 
Some of the molecules identified in the Biolog screen were already known to 
affect pathogenesis in V. cholerae and indicate that the screen worked.  For example, 
chlorpromazine has previously been shown to reduce fluid loss and duration of 
symptoms in cholera patients (10).  The protonophore CCCP collapses the proton 
motive force (PMF), reduces the transduction of the CTXΦ (11), and inhibits V. cholerae 
motility (12).  Procaine (13) and malonic acid (14) have also been shown to reduce toxT 
transcription.  Maltose and procaine, as well as a similar compound lidocaine, were 
chosen for follow up. 
 
Procaine and Lidocaine 
Procaine and lidocaine are both local anesthetics used to reduce pain by 
functioning as sodium channel blockers (15).  Given the evidence in the literature that 








Table A2 Natural compound inhibitors of toxT-GFP in M9 minimal media + NERS. 





Glyoxylic acid 44.8 










investigate the mechanism of action of this compound and a similar compound, 
lidocaine (Figure A1A). First, the toxT-GFP inhibitory activity of lidocaine and procaine 
was confirmed with fresh powders using the toxT-GFP reporter strain (Figures A1B and 
A1C). 
To determine the mechanism of action for procaine-mediated toxT-GFP inhibition, 
RNA was harvested from cultures grown overnight under toxin-inducing conditions with 
20 mM procaine and the levels of toxT, tcpP, aphA, and aphB transcripts were 
quantified by qRT-PCR (see chapter 2 for RNA preparation and qRT-PCR methods).  
Twenty-millimolar procaine was used in these experiments because that is the 
concentration used in previously published reports describing the effects of procaine on 
V. cholerae (13, 16). 
The OD600 and fluorescence of these cultures are shown because there is a 
severe growth defect at this concentration both in a 96-well plate (Figure A2A) and a 
mild one in test tubes (A2B).  Overnight growth in LB pH 6.5 at 30°C shaking resulted in 
high GFP expression, but addition of 20 mM procaine decreased toxT, tcpP, and aphB 
transcripts; aphA transcript was unaffected (Figure A2C).  
 
Maltose 
Maltose was identified as an inhibitor of toxT-GFP expression when cells were 
grown in a different toxin-inducing growth medium- M9 minimal medium with glycerol as 
the carbon source, supplemented with asparagine, glutamate, arginine, and serine 
(NERS).  To determine if maltose also inhibits virulence gene expression in LB pH 6.5 at  
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Figure A1 Procaine and lidocaine inhibit toxT-GFP in a dose-dependent manner. 
A. Structure of lidocaine and procaine.  B. Effects of lidocaine and procaine dose 












































Figure A2 Procaine inhibits toxT expression in a tcpP- and aphB-dependent manner. 
Cultures of V. cholerae O395 + ptoxT-gfp or O395ΔtoxR + ptoxT-gfp were grown 
for 16 hours with or without 20 mM procaine, and the OD600 (A) and fluorescence (B) 
were measured.  C.  Relative gene expression of toxT, tcpP, aphA and aphB in the 







































































































30°C, wild-type cells and an isogenic ΔtoxR mutant were grown overnight under these 
conditions in the presence or absence of 0.4% maltose.  As shown in figure A3A and 
A3B, the addition of maltose did not affect growth, however it reduced toxT-GFP 
expression to levels similar to those of a ΔtoxR mutant, indicating that maltose inhibits 
virulence regardless of the growth conditions used for toxin induction.  Maltose has 
already been shown to decrease CT production and secretion and mal mutants are less 
virulent in infant mouse colonization (17); thus, we did not follow up on this further. 
 
Discussion 
Appendix A describes the identification of 39 inhibitors of toxT-GFP expression in 
V. cholerae.  These were identified by screening for natural product extracts collected 
from marine ecosystems (the CCG natural products collection) and from purified natural 
products (the Biolog collection).  Some of the identified compounds were already known 
to inhibit virulence in V. cholerae, validating the methods used in our screen, but most 
have no known effect to pathogenesis in V. cholerae, and could be used in future 
studies as molecular probes, or for development for antimicrobial therapy. 
Three hits were chosen for follow up studies.  Maltose was found to inhibit toxT-
GFP in two laboratory conditions used to induce toxT gene expression- LB pH 6.5 at 
30°C, and M9 minimal media + NERS at 30°C.  Lidocaine and procaine were 
characterized in more detail and found to inhibit toxT transcription by reducing tcpP and 
aphB transcription.  Very little is known about transcriptional regulation of AphB, though 







Figure A3. Maltose inhibits toxT-GFP expression in LB pH 6.5 at 30°C. 
A. OD600 of the O395 + ptoxT-gfp reporter strain grown in LB pH 6.5 at 30°C with 
0.4% maltose.  B. Fluorescence of the O395 + ptoxT-gfp reporter strain grown in LB pH 






























































































transposon screen as mutants that no longer activate aphB transcription (18).  
Lidocaine and procaine may be beneficial in further exploring how AphB is 
transcriptionally regulated. 
While our focus shifted to the toxtazins, the natural inhibitors identified in these 
screens remain interesting candidates for follow up in future studies.  Further, despite 
there being some literature regarding both procaine and maltose as inhibitors of key V. 
cholerae virulence traits, the mechanisms underlying their effects remain unclear and 
merit further study.   
 
Materials and Methods 
The screens presented here were performed as described elsewhere (Chapter 2; 
(19)) using the natural products from the Center for Chemical Genomics (CCG) at the 
University of Michigan, Ann Arbor MI, USA and the Biolog plates were ordered from 
BIOLOG.  The qRT-PCR analysis was performed as described in Chapter 2 and (19), 
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Small molecule screen for inhibitors of ToxR activity 
 
Summary 
A screen more focused on identifying ToxR inhibitors was designed by using a 
reporter for the gene ompU.  This gene is directly activated by ToxR and does not 
require TcpP, ToxT, or any other component of the toxT branch in the virulence 
regulatory pathway of Vibrio cholerae (1-3).  Compounds that might be expected to 
arise in this type of screen include those that inhibit toxR transcription, about which little 
is known (4, 5), in contrast to the extensive amount of knowledge regarding tcpP 
transcription (6-13). 
To probe the ToxR branch of the virulence cascade in V. cholerae using chemical 
biology, a small molecule screen was performed to identify molecules that inhibit ToxR 
activity using an ompU::sacB reporter strain such that activation of the ompU promoter 
by ToxR results in sacB expression, which is lethal in the presence of sucrose.  
Because ToxR expression is IPTG-inducible, it is possible to differentiate small 
molecule inhibitors that kill V. cholerae by inhibiting ToxR-dependent SacB expression 
(dead only in the presence of IPTG) from those molecules that are generally toxic to V. 




After screening 52,396 compounds from 6 diverse libraries at the Center for 
Chemical Genomics (CCG) at the University of Michigan, 751 compounds were 
identified that reduced growth only when ToxR expression was induced.  Of those, 192 
retained activity in a secondary screen and behaved in a dose-dependent manner.  
Surprisingly, of the ~60,000 compounds screened in both the ToxR and ToxGFP small 
molecule screens (Chapter 2), only four compounds were found to inhibit both screens 
in a dose-dependent manner.  The CCG numbers for these compounds and their 
pAC50 (the inverse log of the concentration required for 50% activity) are shown in 
Table B1. 
To confirm the activity of the best ToxR inhibitors, ToxR activity was determined 
directly by comparing the protein levels of two ToxR-regulated outer membrane proteins, 
OmpU and OmpT, both of which are clearly visible on a coomassie gel.  Lysates of the 
reporter strain (RA63) grown overnight under non-inducing conditions (LB pH 8.5 at 
37°C) in the presence or absence of inhibitors were separated on 12.5% SDS-PAGE 
gels, and OmpU and OmpT were visualized by coomassie staining (Figure B1).  The 
ΔtoxR strain and the reporter strain grown in the absence of IPTG both express higher 
levels of OmpT than OmpU, while wild-type cells and the reporter strain grown in the 
presence of one millimolar IPTG express more OmpU than OmpT.  When the reporter 
strain is grown with IPTG and one of the six identified ToxR inhibitors, the OmpU/OmpT 
ratio resembled a wild-type cell, indicating that despite having been identified as 







CCG # pAC50 ToxR pAC50 ToxGFP 
20343 4.26 5.08 
44180 4.78 4.28 
42440 4.63 4.41 
41503 4.14 4.31 
 
Table B1. Small molecule inhibitors of both ToxR activity at the ompU promoter (ToxR 






Figure B1 OmpU and OmpT expression in the presence of various compounds. 
Cultures of RA63 were grown for 16 hours under toxin non-inducing conditions 
(LB pH 8.5 at 37°C) in the presence or absence of ToxR inhibitors 28724, 28730, 3745, 
21890, 40674, or 33914 and 1mM IPTG to induce ToxR.  Cell lysates were separated 
on SDS-PAGE and OmpU and OmpT were visualized by coomassie staining.   
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21890, 40674, and 33914 slightly increase OmpT expression.  
To determine if our hits were false positives or if the OmpU/OmpT ratio was a 
poor reporter for ToxR activity, we used an alternative secondary screen that measure 
ToxR activity using an O395ΔtoxR ompU-lacZ + pMMB66EH-toxRS strain (RA97).  We 
tested 16 compounds with this assay (CCG numbers 2824, 3274, 3745, 5523, 12812, 
12818, 12849, 20343, 20826, 21440, 21888, 21890, 21895, 21906, 21907, and 22437), 
but none of them showed inhibitory activity of the ToxR-dependent ompU promoter 
(Figure B2).  Because the results of this screen were not confirmed in either of the 
secondary assays, we chose to focus on the ToxGFP screen results. 
 
Material and Methods 
High-throughput small molecule screen for inhibitors of ToxR activity 
The screening strain (RA63) used was  O395ΔtoxR lacZ::ompU-sacB harboring 
the pMMB66EH-toxRS plasmid.  In these cells, ompU activation results in SacB 
production, a protein that confers sucrose sensitivity.  Thus, activation of the ompU 
promoter by ToxR results in sacB expression such that the cells will die in the presence 
of sucrose.  As an additional control, the reporter strain was engineered to expressed 
ToxR from an IPTG-inducible vector, allowing for the differentiation of small molecule 
inhibitors that kill V. cholerae by inhibiting ToxR-dependent SacB expression (dead only 
in the presence of IPTG) from molecules that are generally toxic to V. cholerae (dead in 
the presence or absence of IPTG.) 






Figure B2.   
Strain RA97 (O395ΔtoxR ompU-lacZ + pMMB66EH-toxRS) was grown overnight 
with one millimolar IPTG and either DMSO or compounds at a range of doses.  The 
culture with the highest concentration of compound that did not affect growth was used 
in a Miller assay to determine the activation at the ompU promoter.  Error bars represent 


















































































































out at the Center for Chemical Genomics (University of Michigan), where 52,396 
compounds were tested. Overnight cultures of RA63 were diluted to a final OD600 of 
0.04 into media (LB pH 8.5, 5% sucrose, 100 μg/ml streptomycin, 100 μg/ml ampicillin) 
and either induced with 100 μM IPTG, or left uninduced as a control.  These cultures 
were added to 384-well plates containing various compounds, and allowed to grown for 
seven hours at 37°C.  After this time, the OD600 of each well was read. 
A compound was considered active if it caused a decrease in OD600 of 1 log or 
more compared to the –IPTG control.  When the actives were retested to confirm their 
activity and to measure their dose responsiveness, 751 compounds remained.  Of these, 
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Structure activity relationships of toxtazins A and B 
 
Summary 
Structural analogs of both toxtazin A and toxtazin B were tested for their ability to 
dose-dependently inhibit toxT-GFP expression of V. cholerae grown under toxin-
inducing conditions.  Although the determination of the structure activity relationship 
(SAR) did not result in the identification of more potent molecules, it did uncover the 
pharmacophore for each of the toxtazins, and provided the insight needed to develop a 




The structure activity relationship (SAR) of a molecule is the relationship between 
that molecule’s structure and its biological activity.  Studying SAR allows for the 
determination of the chemical group(s) within a molecule required for producing a 
desired biological effect.  The part of the molecule required for biological activity is 
called the pharmacophore.  SAR data are useful for lead optimization, to decrease 
biodegradation, and increase bioavailability (1).  SAR can also be used to define the 
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parts of a molecule that are dispensible for activity, and can therefore be modified for 
click chemistry. 
Click chemistry is a method of pulling down a compounds biological target out of 
a cell or cell lysate (2, 3).  One of the most common click chemistry reactions uses azide 
alkyne Huisgen cycloaddition using a copper catalyst (4) to covalently bind a small 
molecule to its target.  The target can then be biotinylated, pulled out of the reaction on 
a streptavidin column, and identified by mass spectrometry.  This method of target 




To determine which structural components of the toxtazins are important for their 
biological activity, structural analogs of each compound were tested for their ability to 
inhibit toxT transcription using the toxT-gfp reporter strains.  Analogs available from the 
Center for Chemical Genomics were screened in 384-well plates containing cultures of 
the O395 strain of Vibrio cholerae growing under toxin-inducing conditions (LB pH 6.5 at 
30°C) for 16-18 hrs.  Analogs that decreased toxT-GFP in a dose-dependent manner 
without affecting the OD600 by more than 10% were considered active.  The structure 
and activity of the toxtazin A analogs and the toxtazin B analogs are shown in Tables 
C1 and C2, respectively. 
Based on the results of the SAR studies, pharmacophores for both toxtazin A and 
toxtazin B could be determined, shown in figure C1.  The SO2 moiety of toxtazin A is 
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absolutely required for activity, as all the analogs with modifications to the SO2 group 
lost activity.  The pharmacophore for toxtazin B is less well-defined, as modifications to 
each R group sometimes lost activity and sometimes retained activity, though the R3 
ring could not be removed while the R1 ring could be changed to a methyl group without 
losing activity.  It was suggested that perhaps toxtazin B analogs retain activity so long 
as one R group has an electron-accepting group and one has an electron-donating 
group, but that it did not matter which R group these are on. 
 
Click Chemistry  
In order to pull out the protein target of toxtazin B from a toxtazin B-treated cell 
lysate, we collaborated with Toni Kline, a chemist at the University of Washington, to 
develop photoaffinity probes.  Using the results from the SAR studies, Txtz001 was 
designed (Figure C2) and tested for activity in the toxT-GFP reporter strain.  
Unfortunately, txtz001 did not inhibit toxT-GFP in our assay (Figure C3), and was not 
used in click chemistry because it lacked bioactivity.  Alterations to the txtz probe could 
potentially result in a bioactive probe, and this merits further study. 
 
Discussion 
The SAR studies presented here resulted in a clear pharmacophore for toxtazin 
A, a 4-(difluoromethyl)-2-sulfonylpyrimidine.  Toxtazin A was more potent than any of 
the analogs tested.  The SO2 moiety is absolutely required for function, while the R2 
group seems to be dispensible.  The R1 group can be small or rather bulky, suggesting 
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27091 Active 117477 Inactive
27092 Active 117478 Inactive
27093 Active 117479 Inactive
27095 Active 117584 Inactive
27098 Active 117585 Inactive








Table C2.  SAR of toxtazin B analogs. 
CCG#number Structure Activity CCG#number Structure Activity







131072 Active 28728 Inactive
131073 Active 28729 Inactive
131079 Active 28731 Inactive
131081 Active 28732 Inactive





131074 Inactive 131089 Inactive
131075 Inactive 131094 Inactive
131076 Inactive 131123 Inactive
131078 Inactive 131135 Inactive
131080 Inactive 131137 Inactive
131082 Inactive 131140 Inactive
131084 Inactive 131141 Inactive




131145 Inactive 131162 Inactive
131146 Inactive 131163 Inactive
131147 Inactive 131164 Inactive
131150 Inactive 131165 Inactive
131152 Inactive 131166 Inactive
131153 Inactive 131167 Inactive
131159 Inactive 131172 Inactive











    
 
4-(difluoromethyl)-2-sulfonylpyrimidine      1H, 4H, 5H, 6H-pyrrolo[3,4-c]pyrazol-6-one  







Figure C2.  Chemical structure of txtz001. 
The structure of txtz001 consists of the toxtazin B pharmacophore with a 


























azide for click chemistry to biotin, fluor
azide for click chemistry to biotin, fluor
 chelation of Cu enables lower      








Figure C3.  Bioactivity of the txtz001 probe. 
The RA2 strain containing the ptoxT-gfp reporter plasmid was grown for 16 hours 
under toxin-inducing conditions in the presence or absence of 10 μM toxtazins A, B, or 
txtz001.  An isogenic ΔtoxR strain was used as a control.  The OD600 and GFP 
fluorescence were measured. 
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the SO2 moiety activity is likely not due to it fitting into a small binding pocket.  Based on 
these results, a photoaffinity probe could be made by putting the alkyne and carbene 
the R2 group, or possibly on the R2 group and in place of the trifuloromethyl group of 
the pyrimidine.  This photoaffinity probe, if it retained its ability to inhibit toxT 
transcription, could be used for click chemistry to identify the molecular target(s) of 
toxtazin A in the cells. 
Toxtazin B SAR studies did not present a clearly defined pharmacophore, so we 
conservatively define it as 1H, 4H, 5H, 6H-pyrrolo[3,4-c]pyrazol-6-one, though certainly 
not all molecules with this base structure are active.  We investigated the possibility that 
the molecule retains activity if it has one electron-accepting group and one electron-
donating group, and created the txtz001 probe.  Unfortunately, this probe lost biological 
activity and was not used for click chemistry.  In future iterations of photoaffinity probes, 
the R3 group should not be modified, as the SAR results show that this R group 
tolerates fewer deviations from the parent molecule’s 4-bromophenzenyl group. 
Overall, the SAR studies on toxtazin A and B provide information about what 
submolecular groups are important for biological function, and which are dispensable.  
This information could be used in the future to design a more potent analog, and to 
design a photoaffinity probe for click chemistry to pull down the in vivo target of these 
compounds.
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Material and Methods 
Analysis of toxtazin A and B analogs 
The screening strain used was wild type O395 harboring a plasmid with the toxT 
promoter driving expression of GFPmut3 (strain RA2).  Analogs were tested for dose-
dependent activity by adding them to 384-well plates containing cultures diluted to a 
final OD600 of 0.02 in LB pH 6.5, and allowing cultures to grow for 16-18 hours at 30°C.  
The OD600 and GFP ((excitation λ = 385 nm, emission λ = 425 nm) levels were 
measured to monitor for growth and toxT-GFP expression.  Analogs were considered 
active if they caused a dose-dependent decrease in GFP levels without affecting the 
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